

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 September 2002 (12.09.2002)

PCT


(10) International Publication Number
WO 02/069907 A2

- (51) International Patent Classification⁷: **A61K** 91326 (US). **DIAMOND, David, C.** [US/US]; 23135 Schoenborn Street, West Hills, CA 91304 (US).
- (21) International Application Number: PCT/US02/07204
- (22) International Filing Date: 7 March 2002 (07.03.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/274,063 7 March 2001 (07.03.2001) US
- (71) Applicant (for all designated States except US): **CTL IMMUNOTHERAPIES CORP.** [US/US]; 9340 DeSoto Avenue, Chatsworth, CA 91311 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SIMARD, John, J.L.** [CA/US]; 11918 Laughton Way, Northridge, CA
- (74) Agent: **ARNO, Thomas, R.**; Knobbe, Martens, Olson & Bear, LLP, 16th floor, 620 Newport Center Beach Drive, Newport Beach, CA 92660 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EC, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,

[Continued on next page]

(54) Title: ANTI-NEOVASCULATURE PREPARATIONS FOR CANCER

ED-B 29-38 specific lysis by CTL from
peptide immunized HHD-A2 mice



(57) Abstract: Disclosed herein are immunogenic compositions, methods of designing immunogenic compositions, methods of treatment using immunogenic compositions, methods of evaluating cell-mediated immunity resulting from immunogenic compositions, research models, and methods of making research models, all of which relate to targeting tumor vasculature.

WO 02/069907 A2



GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *without international search report and to be republished
upon receipt of that report*

ANTI-NEOVASCULATURE PREPARATIONS FOR CANCER

Background of the Invention

Description of the Related Art

The treatment of cancer has remained challenging despite the advances in biomedicine. In recent years two approaches have been described showing much promise: therapeutic vaccines and anti-angiogenesis.

Therapeutic vaccines rely on the observation that cancerous tissues generally express certain antigens preferentially, collectively tumor-associated antigens (TuAA). TuAA include proteins normally expressed selectively by the tissue from which the cancer derives (differentiation antigens), proteins that are associated with a different stage of development (oncofetal and cancer-testis antigens), proteins that are created by aberrant chromosomal rearrangement, or proteins that are derived from oncogenic viruses. These TuAA, or fragments of them, are then used as immunogens in vaccines intended to stimulate cellular immunity, particularly cytotoxic T lymphocytes (CTL), capable of killing the tumor cells.

The anti-angiogenesis approach takes advantage of the need of tumors to recruit a blood supply to support their continued growth. To accomplish this, tumors secrete angiogenic factors that promote the growth of new blood vessels. The anti-angiogenesis approach aims to disrupt a tumor's supply of nutrients to cause it to die, or at least limit its growth. Attempts at this approach have sought chemotherapeutic drugs used directly against a variety of anti-angiogenic factors and angiogenesis.

Summary of the Invention

The invention disclosed herein is directed to compositions designed to stimulate cellular immune responses targeting tumor-associated neovasculature (TuNV). In one embodiment of the invention the compositions stimulate a CTL response. Such compositions may include one or more epitopes of the target antigen. One aspect of this embodiment specifically includes a housekeeping epitope, another specifically includes an immune epitope or epitope cluster, and another aspect specifically combines housekeeping and immune epitopes.

Embodiments of the invention relate to the use of prostate specific membrane antigen (PSMA) as the target antigen of the composition. Aspects of this embodiment include various epitopes derived from PSMA provided directly as polypeptide, or as a nucleic acid capable of conferring expression of the epitope. Other embodiments relate to the use of other TuNV-associated antigens.

In other embodiments of the invention, compositions are directed against both the TuNV and against TuAA expressed by the cancerous cells, by combining immunogens derived from both sources into a single formulation or method or treatment.

Preclinical evaluation of the compositions of this invention can be accomplished using adoptive transfer of immunized T cells into SCID mice bearing microvasculature formed from implanted human dermal microvascular endothelial cells (HDMEC). Preclinical evaluation can also be accomplished through the use of HLA-transgenic mice immunized with compositions comprised of epitopes conserved between mice and humans.

Embodiments of the invention relate to methods of evaluating cell-mediated immunity. The methods can include the steps of implanting vascular cells into an immunodeficient mammal; establishing an immune response in the mammal; and assaying a characteristic to determine cell-mediated immunity in the mammal. The cell-mediated immunity can be directed against a neovasculature antigen, for example. The neovasculature antigen can be preferentially expressed by tumor-associated neovasculature, for example, and in preferred embodiments can be prostate specific membrane antigen (PSMA), vascular endothelial growth factor receptor 2 (VEGFR2), and the like. The establishing step can be achieved, for example, by adoptive transfer of T-cells to the mammal, by contacting the mammal with an antigen, and the like. The cell-mediated immunity can be mediated by cytotoxic T lymphocytes. The vascular cells can be vascular endothelial cells, such as, for example, human dermal microvascular endothelial cells (HDMEC), telomerase-transformed endothelial cells, and the like. The immunodeficient mammal can be a mouse, such as for example a SCID mouse. The characterizing step can include assessing a parameter, such as for example, vessel formation, vessel destruction, vessel density, proportion of vessels carrying blood of the host mammal, and the like.

The methods can further include the step of implanting tumor cells or tumor tissue in the mouse. The characterizing step can include assessing a parameter, such as, for example, tumor presence, tumor growth, tumor size, rapidity of tumor appearance, dose of vaccine required to inhibit or prevent tumor establishment, tumor vascularization, a proportion of necrotic tissue within the tumor, and the like.

The methods can further include the steps of providing a first population of mammals and a second populations of mammals; establishing cell-mediated immunity in the first population; differentially establishing cell-mediated immunity in the second population; and comparing a result obtained from the first population of mammals to a result obtained from the second population of mammals. The cell-mediated immunity of the first population can include, for example, naïve immunity, immunity to an irrelevant epitope, and the like.

Other embodiments relate to methods of evaluating cell-mediated immunity, including immunity directed against a neovasculature antigen. The methods can include the steps of implanting or injecting MHC-transgenic tumor cells into an MHC-transgenic mammal; establishing an immune response in the mammal; and assaying a characteristic to determine cell-mediated immunity in the mammal. The MHC-transgenic mammal can be an HLA-transgenic mammal, such as, for example an HLA-A2 transgenic mammal. In preferred embodiments the mammal can be a mouse. The cell-mediated immunity can be established by vaccination, which in preferred embodiments can take place prior to, concurrent with, or subsequent to transfer of the tumor cells, for example. In preferred embodiments the cell-mediated immunity can be mediated by cytotoxic T lymphocytes. The neovasculature antigen can be preferentially expressed by tumor-associated neovasculature and can also be a tumor-associated antigen. Preferably, the antigen can be the ED-B domain of fibronectin. The characterizing step can include, for example, assessing a parameter, including tumor presence, tumor growth, tumor size, rapidity of tumor appearance, dose of vaccine required to inhibit or prevent tumor establishment, tumor vascularization, a proportion of necrotic tissue within the tumor, and the like. The methods can further include the steps of providing a first population of mammals and a second populations of mammals; establishing cell-mediated immunity in the first population; differentially establishing cell-mediated immunity in the

second population; and comparing a result obtained from the first population of mammals to a result obtained from the second population of mammals. The cell-mediated immunity of the first population can include naïve immunity, immunity to an irrelevant epitope, and the like.

5 Still further embodiments relate to methods of treating neoplastic disease, including the step of immunizing a mammal to induce a cellular immune response directed against an antigen differentially expressed by tumor-associated neovasculature. The differentially expressed antigen can be a protein, such as, for example prostate specific membrane antigen, vascular endothelial growth factor receptor 2 (VEGFR2), and the like. In other preferred
10 embodiments, the antigen can be the ED-B domain of fibronectin. The immunization can be carried out, for example, with at least one peptide derived from the sequence of the protein, with a nucleic acid capable of conferring expression of the protein or peptides, and the like. The at least one peptide can include a housekeeping epitope, for example, and in preferred embodiments can be co-C-terminal with the housekeeping epitope. The methods can further include at least one additional peptide, wherein the at least one additional peptide includes an immune epitope. The methods can include an additional step wherein the mammal is treated with an anti-tumor therapy active directly against cancerous cells. The anti-tumor therapy can be immunization against a tumor-associated antigen. Preferably, the cellular immune
15 response can include a CTL response.

Other embodiments relate to immunogenic compositions. The immunogenic compositions can include at least one immunogen corresponding to an antigen expressed by tumor-associated neovasculature, wherein the composition can induce a cellular immune response. The immunogen can be one that is not associated with a cell conspecific with the recipient. The antigen can be a protein, such as, for example prostate specific membrane antigen, vascular
20 endothelial growth factor receptor 2 (VEGFR2), and the like. In other preferred embodiments the antigen can be the ED-B domain of fibronectin. The immunogen can include at least one peptide. The compositions can include a nucleic acid capable of conferring expression of the antigen, and wherein the antigen is a protein or a peptide. The compositions can include at least one peptide that includes a housekeeping epitope, and in preferred embodiments the at least one peptide can be co-C-terminal with the housekeeping epitope. Also, the compositions can additionally
25 include at least one peptide that includes an immune epitope. The compositions can include at least one immunogen corresponding to a tumor-associated antigen. In preferred embodiments the cellular immune response can include a CTL response.

Embodiments relate to methods of anti-tumor vaccine design. The methods can include the steps of identifying an antigen differentially expressed by tumor-associated neovasculature; and incorporating a component of
30 the antigen into a vaccine. The component can include, for example, a polypeptide fragment of the antigen, a nucleic acid encoding the antigen or a fragment of the antigen, and the like.

Further embodiments relate to methods of making a research model. The methods can include implanting a vascular cell and a tumor cell into an immunodeficient mammal. The tumor cell and the vascular cell can be implanted adjacent to one another. The vascular cell can be a vascular endothelial cell, such as for example HDMEC. In preferred

embodiments the vascular endothelial cell can be telomerase-transformed. The immunodeficient mammal can be a mouse, such as, for example, a SCID mouse.

Other embodiments relate to research models. The research models can include an immunodeficient mammal. The mammal can include an implanted vascular cell and an implanted tumor cell. The vascular cell and the tumor cell can be implanted adjacent to one another.

Brief Description of the Drawings

Figure 1A, B, and C show results of N-terminal pool sequencing of a T=60 min. time point aliquot of the PSMA₁₆₃₋₁₉₂ proteasomal digest.

Figure 2 shows binding curves for HLA-A2:PSMA₁₆₈₋₁₇₇ and HLA-A2:PSMA₂₈₈₋₂₉₇ with controls.

Figure 3 shows results of N-terminal pool sequencing of a T=60 min. time point aliquot of the PSMA₂₈₁₋₃₁₀ proteasomal digest.

Figure 4 shows binding curves for HLA-A2:PSMA₄₆₁₋₄₆₉, HLA-A2:PSMA₄₆₀₋₄₆₉, and HLA-A2:PSMA₆₆₃₋₆₇₁, with controls.

Figure 5 shows the results of a (gamma)-IFN-based ELISPOT assay detecting PSMA₄₆₃₋₄₇₁-reactive HLA-A1⁺ CD8⁺ T cells.

Figure 6 shows blocking of reactivity of the T cells used in figure 10 by anti-HLA-A1 mAb, demonstrating HLA-A1-restricted recognition.

Figure 7 shows a binding curve for HLA-A2:PSMA₆₆₃₋₆₇₁, with controls.

Figure 8 shows a binding curve for HLA-A2:PSMA₆₆₂₋₆₇₁, with controls.

Figure 9 shows epitope specific lysis by CTL from HHD-A2 mice immunized with ED-B 29-38 peptide.

Detailed Description of the Preferred Embodiment

Embodiments of the invention disclosed herein provide compositions, methods of composition or vaccine design, and methods of treatment related to the generation of a cellular immune response, preferably, a T cell response and, more preferably, a CTL response, directed against the neovasculature of tumors. Such methods and compositions are particularly useful in the treatment and prevention of cancer. Other embodiments relate to composition evaluation models.

Compositions, Composition Design, and Treatment Using the Compositions

Embodiments of the invention relate to immunogenic compositions, including vaccines, for the generation of a cellular immune response, particularly a T cell response and specifically a CTL response, directed against tumor neovasculature (TuNV). "Tumor neovasculature" is broadly meant to include any vasculature found in or around tumor masses, vasculature which supports or is necessary for tumor growth, and the like. It should be noted, and one of skill in the art will appreciate, that although the discussion herein refers generally to the tumors and tumor neovasculature, the embodiments of the present invention also can be applied to other conditions or disease states associated with inappropriate angiogenesis.

Until now the design of anti-tumor vaccines has concentrated on antigens expressed by the malignant cells themselves. However, larger tumors are complex structures and not simply a homogeneous mass of cells. All cells, particularly rapidly growing cells, need a supply of nutrients (oxygen, glucose, amino acids, etc.), as well as a means of removal of metabolic wastes, in order to remain metabolically active and intact. This is normally accomplished by the flow of blood and lymph through the various organs of the body. At a cellular level, the tissues of the body are permeated by a fine network of capillaries – tiny vessels through which nutrients and waste products can be exchanged with the surrounding cells by diffusion. Diffusion is effective over relatively short distances. The capillary beds are so extensive that generally cells are at most located only a few cells away from a capillary. If a tumor merely grew by propagation of its malignant cells, soon those cells in the interior of the mass would be unable to sustain themselves. In fact, the interiors of unvascularized tumors often contain necrotic tissue. Thus, in order to grow unchecked, tumors secrete factors that promote the in-growth of new blood vessels, namely TuNV. Since the TuNV expresses antigens differentiating it from other tissues, cancer can be treated with therapeutic compositions directed against the TuNV, instead of directly targeting the cancerous cells themselves. Suitable TuNV antigens can include those that are expressed generally in neovasculature or preferentially by TuNV, for example.

In some embodiments of the invention the compositions can include, for example, an epitopic peptide or peptides. Immune epitopes may be provided embedded in epitope clusters and protein fragments. Housekeeping epitopes can be provided with the proper C-terminus. In other embodiments of the invention the compositions can include nucleic acids capable of conferring expression of these epitopes on pAPC, for example.

In preferred embodiments, the compositions can be administered directly to the lymphatic system of a mammal being treated. This can be applied to both polypeptide and nucleic acid based compositions. Administration methods of this type, and related technologies, are disclosed in U.S. Patent Application No. 09/380,534, filed on September 1, 1999, and a Continuation-in-Part thereof, filed on February 2, 2001; U.S. Patent Application No. 09/776,232, both entitled "A METHOD OF INDUCING A CTL RESPONSE,".

In a preferred embodiment, destruction of the blood vessels in a tumor by action of a composition of the invention can eliminate all of the cells in a tumor. However, small tumors, including micrometastases, are typically unvascularized. Additionally, unvascularized tumors that instead apparently rely on blood flow through channels penetrating the tumor mass have been reported (Maniotis, A.J., et al. Am. J. Pathol. 155: 739-752, 1999). Thus in other embodiments, the compositions are generally effective as tumor control agents that may not eradicate all cancer cells. Accordingly, the invention provides tools for eliminating tumors, controlling tumor growth, reducing tumor burden, improving overall clinical status, and the like. In some embodiments, it can be desirable to combine these compositions with other treatments that target the cancerous cells directly. Additionally there is evidence that the vasculature in tumors can be mosaic in nature consisting of both endothelial and cancer cells (Chang, Y.S., et al. Proc. Natl. Acad. Sci. USA 97:14608-14613, 2000). Thus, in some embodiments of the invention a course of composition treatment can be followed by administration of a bio- or chemotherapeutic agent. In a particularly preferred

embodiment, treatment can include administration of a TuAA directed composition concurrent or subsequent to administration of the anti-TuNV composition.

As mentioned above, suitable TuNV antigens for the compositions can include those that are expressed generally in neovasculature or preferentially by TuNV, for example. A variety of techniques for discovery of TuAA are known in the art. Examples of these techniques include, without limitation, differential hybridization and subtractive hybridization, including use of microarrays; expression cloning; SAGE (serial analysis of gene expression); SEREX (serological identification of antigens by recombinant expression cloning); in situ RT-PCT; immunohistochemistry (as was the case for PSMA); EST analysis; variously using bulk, sectioned, and/or microdissected tissue; and the like. Utilization of these and other methods provides one of skill in the art the techniques necessary to identify genes and gene products contained within a target cell that may be used as antigens of immunogenic compositions. The techniques are applicable to TuAA discovery regardless of whether the target cell is a cancer cell or an endothelial cell. Any identified antigen can be scrutinized for epitopes, which can be used in embodiments of the invention.

The endothelial cells making up the lining of the vasculature can express housekeeping proteasomes. Thus, compositions targeting endothelial cells can be comprised of peptides, or nucleic acids conferring expression of the peptides, corresponding to the digestion products of the housekeeping proteasome (i.e. housekeeping epitopes). IFN- γ (gamma), secreted by activated cells of the immune system, can induce expression of the immunoproteasome in the target cells. Generally, the immunoproteasome is constitutive in professional antigen presenting cells (pAPC). Thus, it can be helpful to include immune epitopes or epitope clusters in CTL-inducing compositions to ensure that there are CTL able to recognize the target cell regardless of the state that the target cell is in. This can be particularly true with endothelial cells, which readily assume antigen presentation functions. These concepts are more fully explained in U.S. Patent Application Nos. 09/560,465, filed on April, 28, 2000; 10/005,905, filed on November 7, 2001; and a continuation thereof, U.S. Application No. _____ filed on December 7, 2001, attorney docket number CTLIMM.21CP1C, each of which is entitled "EPI TOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS,".

As discussed above, the immunogenic compositions, including in preferred embodiments, vaccines, can include TuNV antigens and epitopes, for example. The epitopes can include one or more housekeeping epitopes and/or one or more immune epitopes. Specific epitopes useful in compositions can be identified using the methods disclosed in U.S. Patent Application No. 09/561,074 entitled "METHOD OF EPI TOPE DISCOVERY," filed on April 28, 2000. For example, peptide sequences that are known or predicted to bind to some MHC restriction element can be compared to fragments produced by proteasomal digestion in order to identify those that are co-C-terminal.

Examples of useful epitopes for the embodiments of the invention, including epitopes of ED-B and PSMA, are disclosed in a U.S. Provisional Patent Application No. _____, entitled "EPI TOPE SEQUENCES," attorney docket number CTLIMM.027PR; filed on even date with this application, March 7, 2002, and two U.S. Provisional Patent Applications, each entitled "EPI TOPE SEQUENCES;" Application No. 60/282,211, filed on April 6, 2001 and 60/337,017, filed on November 7, 2001. Each of these applications is incorporated herein by reference in its entirety.

PSMA is one example of a TuAA that can be targeted in some embodiments. PSMA is expressed in the neovasculature of most tumor types, but not by the vascular endothelium of normal tissues (Chang, S.M. et al., *Cancer Res.* 59(13):3192-8, 1999; *Clin Cancer Res.* 10:2674-81, 1999). PSMA is a membrane antigen, and as such, it may be possible to attack PSMA-expressing TuNV with monoclonal antibody (mAb). However, the effectiveness of mAb in the treatment of cancer has proved to be more difficult than initially anticipated. Moreover, as other antigens are discovered to be associated with the TuNV, it is likely that many of them will prove not to be expressed at the vasculature surface, making them inaccessible to mAb attack.

T cells, particularly CTL, on the other hand, survey the expression of internal components of the cell through the process of major histocompatibility complex (MHC)-restricted antigen presentation. The parameters for determining the effectiveness of T cell-activating vaccines and compositions against self-antigens are subtle. Some of the critical features and parameters relating to appropriate epitope selection are disclosed in U.S. Patent Application No. 09/560,465 entitled "EPITOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS," filed on April 28, 2001; U.S. Patent Application No. 09/561,074 entitled "METHOD OF EPITOPE DISCOVERY," filed on April 28, 2001; and U.S. Patent Application No. 09/561,571 entitled "EPITOPE CLUSTERS," filed on April 28, 2001. Features of DNA vaccine design promoting epitope synchronization are disclosed in U.S. Patent Application No. 09/561,572 entitled "EXPRESSION VECTORS ENCODING EPITOPES OF TARGET-ASSOCIATED ANTIGENS," filed on April 28, 2001 and U.S. Provisional Application No. 60/336,968 entitled "EXPRESSION VECTORS ENCODING EPITOPES OF TARGET-ASSOCIATED ANTIGENS AND METHODS FOR THEIR DESIGN," filed on November 7, 2001. Particularly effective means of vaccine delivery are described in U.S. Patent Application No. 09/380,534, filed on September 1, 1999, and a Continuation-in-Part thereof, U.S. Patent Application No. 09/776,232, filed on February 2, 2001, both entitled "A METHOD OF INDUCING A CTL RESPONSE." Each of the above-mentioned references is incorporated herein by reference in its entirety.

Another example of a TuNV antigen that can be used in embodiments is fibronectin, preferably the ED-B domain. Fibronectin is subject to developmentally regulated alternative splicing, with the ED-B domain being encoded by a single exon that is used primarily in oncofetal tissues. Matsuura, H. and S. Hakomori *Proc. Natl. Acad. Sci. USA* 82:6517-6521, 1985; Carnemolla, B. et al. *J. Cell Biol.* 108:1139-1148, 1989; Lordon-Rosa, B. et al. *Cancer Res.* 50:1608-1612, 1990; Nicolo, G. et al. *Cell Differ. Dev.* 32:401-408, 1990; Borsi, L. et al. *Exp. Cell Res.* 199:98-105, 1992; Oyama, F. et al. *Cancer Res.* 53:2005-2011, 1993; Mandel, U. et al. *APMIS* 102:695-702, 1994; Farnoud, M.R. et al. *Int. J. Cancer* 61:27-34, 1995; Pujuguet, P. et al. *Am. J. Pathol.* 148:579-592, 1996; Gabler, U. et al. *Heart* 75:358-362, 1996; Chevalier, X. *Br. J. Rheumatol.* 35:407-415, 1996; Midulla, M. *Cancer Res.* 60:164-169, 2000.

The ED-B domain is also expressed in fibronectin of the neovasculature Kaczmarek, J. et al. *Int. J. Cancer* 59:11-16, 1994; Castellani, P. et al. *Int. J. Cancer* 59:612-618, 1994; Neri, D. et al. *Nat. Biotech.* 15:1271-1275, 1997; Karelina, T.V. and A.Z. Eisen *Cancer Detect. Prev.* 22:438-444, 1998; Tarli, L. et al. *Blood* 94:192-198, 1999; Castellani, P. et al. *Acta Neurochir. (Wien)* 142:277-282, 2000. As an oncofetal domain, the ED-B domain is

commonly found in the fibronectin expressed by neoplastic cells, in addition to being expressed by the TuNV. Therefore, CTL-inducing compositions targeting the ED-B domain can exhibit two mechanisms of action: direct lysis of tumor cells, and disruption of tumor blood supply through destruction of the TuNV.

It should be noted that expression of the fibronectin ED-B domain has been reported in both tumor-associated and normal neovasculature (Castellani, P. et al. *Int. J. Cancer* 59:612-618, 1994). Thus, compositions based on it, or similarly expressed antigens, can be effective against other conditions associated with inappropriate angiogenesis. Further, as CTL activity can decay rapidly after withdrawal of the composition, interference with normal angiogenesis can be minimal.

Other targets for the immunogenic compositions include growth factor receptors, including those associated with vascular cells. One such example is the vascular endothelial growth factor receptor 2 (VEGFR2). U.S. Patent No. 6,342,221 includes discussion of VEGF and VEGFR2. One of skill in the art will appreciate that any other antigen or protein associated with vascular cells can be a target for the immunogenic compositions, including those that are presently known and those yet to be identified.

Animal Models, Methods of Making the Models, and Composition Evaluation

Compositions designed based upon the preceding considerations are effective against the various targets. However, additional evaluation can be easily performed at any time, but preferably in a pre-clinical setting. For example, such evaluation can be used in order to further aid in composition design. Other embodiments of the invention relate to methods of evaluating the immunogenic compositions. The compositions of the present invention can be easily evaluated by one of skill in the art using animal models for composition evaluation. For example, following the routine procedures below, one of skill in the art can evaluate TuNV compositions quickly and efficiently. Thus, using the models or guidance described herein, one of skill in the art can evaluate any TuNV composition for any TuNV antigen with little or no experimentation. Further embodiments relate to methods of making the animal research models. Other embodiments relate to the research model animals. These embodiments are set forth more fully below.

Xenotransplanted Human Vasculature-Based Model

Some embodiments relate to a model system for studying the mechanisms of human microvessel formation. For example, in some embodiments, the model system can be used for preclinical evaluation of compositions. The model involves the subcutaneous implantation of telomerase-transformed human dermal microvascular endothelial cells (HDMEC) mixed with MATRIGEL (Becton Dickinson) into SCID mice. Subcutaneous implantation of telomerase-transformed HCMEC is described in Yang, J. et al. *Nature Biotech* 19:219-224, 2001. T cells activated by the compositions of this invention can be adoptively transferred, for example, into such implanted mice, and the ability of the T cells to destroy, or prevent the formation of, such human microvessels can be assessed. In other embodiments, the mouse can be directly vaccinated and evaluated. Also, in still further embodiments, the model system can be further adapted for testing compositions effective in non-human species by substituting DMEC from other species and species-matched telomerase, and by using analogous reagents to those described below for the human system.

The MHC-restriction elements presenting the epitopes of the composition being tested, preferably, are shared by the HDMEC line implanted into the mice. The T cells can be derived from *in vitro* immunization of human T cells, or by immunization of HLA-transgenic mice (procedures for which are well known in the art and examples of which are provided in the above incorporated patent applications). Use of T cells generated in HLA-transgenic mice allows
5 matching of genetic backgrounds between the adoptively transferred T cells and the host, thereby reducing the possibility of allogeneic or xenogeneic reactions that might complicate interpretation of the results. However, depending on the mouse strains available, this might require cross-breeding to get the HLA-transgene and SCID phenotype on the same genetic background. In the alternative, the donor T cells (human or murine) can be subjected to one or more rounds of *in vitro* stimulation to enrich for the desired population or establish a clone, and thereby similarly
10 avoid undesired reactivities.

Techniques for *in vitro* immunization are known in the art, for example, Stauss et al., *Proc. Natl. Acad. Sci. USA* 89:7871-7875, 1992; Salgaller et al. *Cancer Res.* 55:4972-4979, 1995; Tsai et al., *J. Immunol.* 158:1796-1802, 1997; and Chung et al., *J. Immunother.* 22:279-287, 1999. Once generated, whether *in vivo* or *in vitro*, sufficient numbers of such T cells can be obtained by expansion *in vitro* through stimulation with the compositions of this
15 invention and/or cytokines (see for example Kurokawa, T. et al., *Int. J. Cancer* 91:749-746, 2001) or other mitogens. These T cells can constitute a clone or a polyclonal population recognizing one or more epitopes. In preferred embodiments, on the order of 10^5 to 10^8 cells are transferred for adoptive transfer experiments in mice. (See for example Drobyski, W.R. et al. *Blood* 97:2506-2513, 2001; Seeley B.M. et al. *Otolaryngol. Head Neck Surg.* 124:436-441, 2001; Kanwar, J.R. et al. *Cancer Res.* 61:1948-1956, 2001). Clones and otherwise more enriched populations
20 generally require the transfer of fewer cells.

Transfer of the T cells can take place shortly before, concurrent with, or subsequent to implantation or establishment of the HDMEC. Parameters that can be assessed to evaluate effectiveness of the compositions include vessel formation, changes in vessel density, and ability to carry mouse blood (as described in Yang et al.), and the like. Assessment can be carried out as early as one week, and at least as long as 6 weeks, after implantation of
25 telomerase-transformed HDMEC, preferably after 2 weeks; and from a day to more than 6 weeks after T cell transfer, preferably after 1 to 3 weeks. Generally, assessment can include comparison of mice receiving T cells reactive with the target antigen with mice receiving naïve (including sham-immunized), or irrelevant epitope-reactive T cells.

Relevant antigens can be expressed generally in neovasculature or preferentially by TuNV. Expression can be confirmed by a variety of techniques known in the art, including immunohistochemistry and RT-PCR. For example,
30 tumor cells can be implanted along with the HDMEC. This can result in inducing expression of antigens preferentially expressed by TuNV. In one example, this can be accomplished by implanting a block of tumor tissue adjacent to the HDMEC-containing MATRIGEL implant, injecting tumor cells at the site of the implant, implanting tumor cell-containing MATRIGEL adjacent to the HDMEC-containing MATRIGEL implant, incorporating both tumor cells and HDMEC into the same MATRIGEL implant or by any other suitable method. As discussed above, in some embodiments, tumor cells can

be implanted along with vascular cells. The animals so made, can be used as research models. Additional variations will be apparent to one of skill in the art.

HLA-transgenic Animal Model

For antigens that are conserved, in sequence and/or expression profile, between human and the model species, HLA-transgenic strains allow another approach, namely vaccination of the model animal to combat a syngeneic tumor. The ED-B domain of fibronectin provides such an opportunity, as it is a marker of angiogenesis and has identical amino acid sequence in both humans and mice (Nilsson, F. et al. *Cancer Res.* 61:711-716, 2001). Moreover, spontaneous tumor tissue from a strain of HLA-A2 transgenic mice has been isolated and propagated. Epitope discovery and selection, and composition design and delivery for CTL inducing compositions are discussed above.

The tumor cell line, M1, is derived from a spontaneous salivary glandular cystadenocarcinoma. The M1 tumor cell line and methods of using the same is disclosed in U.S. Provisional Application No. _____, attorney docket number CTLIMM.028PR, filed on even date with this application, March 7, 2001, entitled "AN HLA-TRANSGENIC MURINE TUMOR CELL LINE." The tumor cell line, can arise in individuals of the HHD-A2 transgenic mouse strain of S. Pascolo et al. (*J. Exp. Med.* 185:2043-2051, 1997). These mice express a single monochain class I molecule comprising human β (beta)2-microglobulin, and α 1 (alpha-1), and α 2 (alpha-2) domains of HLA-A2.1 with the balance of the molecule derived from the murine class I molecule H2D^b. Blocks of tumor can be transplanted into new individuals where the tumor will re-grow, commonly within 1-3 weeks, with 3 mm blocks growing to 3 cm. Alternatively, tumor tissue can be disaggregated and the tumor cells grown *in vitro*. Upon harvest, the tumor cells can be injected subcutaneously into the neck or abdomen (2.5×10^6 cells for 1-3 successive days), to result in a visible tumor in approximately 5-12 weeks for early passage cells. After the cells have become better adapted to growth *in vitro*, single injections of 1×10^6 to 1×10^7 cells lead to visible tumor in ten days. Generally, the initial tumor consistently occurs in the vicinity of the salivary glands, but secondary tumors can also occur in a variety of locations, including kidney, lung, liver, and abdominal muscle.

To evaluate the efficacy of a composition, it can be administered before, concurrent with, or subsequent to establishment of the tumor, depending on the expected mechanism of the composition. For therapeutic compositions intended to be used with some sort of debulking technique (e.g. surgery), concurrent administration can be appropriate. The better established the tumor is before treatment begins, the more stringent the test.

Both animal evaluation models have been described for the testing of human compositions. However, application to veterinary compositions is analogous, requiring only the substitution of species-matched endothelial cells, MHC, TuAA, etc.

The following examples are intended for illustration purposes only, and should not be construed as limiting the scope of the invention in any way.

EXAMPLES**Example 1.**

A preclinical study was carried out using the already identified antigens PSMA and ED-B disclosed herein. The results of the study revealed excellent candidate epitopes. See table 9 below.

Example 1.1**Cluster Analysis (PSMA₁₆₃₋₁₉₂)**

A peptide, AFSPQGMPEGDLVYVNYARTEDFFKLERDM, PSMA₁₆₃₋₁₉₂ (SEQ ID NO. 3), containing an A1 epitope cluster from prostate specific membrane antigen, PSMA₁₆₈₋₁₉₀ (SEQ ID NO. 4) was synthesized using standard solid-phase F-moc chemistry on a 433A ABI Peptide synthesizer. After side chain deprotection and cleavage from the resin, peptide first dissolved in formic acid and then diluted into 30% Acetic acid, was run on a reverse-phase preparative HPLC C4 column at following conditions: linear AB gradient (5% B/min) at a flow rate of 4 ml/min, where eluent A is 0.1% aqueous TFA and eluent B is 0.1% TFA in acetonitrile. A fraction at time 16.642 min containing the expected peptide, as judged by mass spectrometry, was pooled and lyophilized. The peptide was then subjected to proteasome digestion and mass spectrum analysis essentially as described above. Prominent peaks from the mass spectra are summarized in Table 1.

Table 1. PSMA₁₆₃₋₁₉₂ Mass Peak Identification.

PEPTIDE	SEQUENCE	CALCULATED MASS (MH ⁺)
163-177	AFSPQGMPEGDLVYV	1610.0
178-189	NYARTEDFFKLE	1533.68
170-189	PEGDLVYVNYARTEDFFKLE	2406.66
178-191	NYARTEDFFKLERD	1804.95
170-191	PEGDLVYVNYARTEDFFKLERD	2677.93
178-192	NYARTEDFFKLERDM	1936.17
163-176	AFSPQGMPEGDLVY	1511.70
177-192	VNYARTEDFFKLERDM	2035.30
163-179	AFSPQGMPEGDLVYVNY	1888.12
180-192	ARTEDFFKLERDM	1658.89
163-183	AFSPQGMPEGDLVYVNYARTE	2345.61
184-192	DDFKLERDM	1201.40
176-192	YVNYARTEDFFKLERDM	2198.48
167-185	QGMPEGDLVYVNYARTEDF	2205.41
178-186	NYARTEDFF	1163.22

Boldface sequences correspond to peptides predicted to bind to MHC, see Table 2.

N-terminal Pool Sequence Analysis

One aliquot at one hour of the proteasomal digestion was subjected to N-terminal amino acid sequence analysis by an ABI 473A Protein Sequencer (Applied Biosystems, Foster City, CA). Determination of the sites and efficiencies of cleavage was based on consideration of the sequence cycle, the repetitive yield of the protein sequencer, and the relative yields of amino acids unique in the analyzed sequence. That is if the unique (in the analyzed sequence) residue X appears only in the nth cycle a cleavage site exists n-1 residues before it in the N-terminal direction. In addition to helping resolve any ambiguity in the assignment of mass to sequences, these data also provide a more reliable indication of the relative yield of the various fragments than does mass spectrometry.

For PSMA₁₆₃₋₁₉₂ (SEQ ID NO. 3) this pool sequencing supports a single major cleavage site after V₁₇₇ and several minor cleavage sites, particularly one after Y₁₇₉. Reviewing the results presented in figures 1A-C reveals the following:

S at the 3rd cycle indicating presence of the N-terminus of the substrate.

Q at the 5th cycle indicating presence of the N-terminus of the substrate.

N at the 1st cycle indicating cleavage after V₁₇₇.

N at the 3rd cycle indicating cleavage after V₁₇₅. Note the fragment 176-192 in Table 1.

T at the 5th cycle indicating cleavage after V₁₇₇.

T at the 1st - 3rd cycles, indicating increasingly common cleavages after R₁₈₁, A₁₈₀ and Y₁₇₉. Only the last of these correspond to peaks detected by mass spectrometry; 163-179 and 180-192, see Table 1. The absence of the others can indicate that they are on fragments smaller than were examined in the mass spectrum.

K at the 4th, 8th, and 10th cycles indicating cleavages after E₁₈₂, Y₁₇₉, and V₁₇₇, respectively, all of which correspond to fragments observed by mass spectroscopy. See Table 1.

A at the 1st and 3rd cycles indicating presence of the N-terminus of the substrate and cleavage after V₁₇₇, respectively.

P at the 4th and 8th cycles indicating presence of the N-terminus of the substrate.

G at the 6th and 10th cycles indicating presence of the N-terminus of the substrate.

M at the 7th cycle indicating presence of the N-terminus of the substrate and/or cleavage after F₁₈₅.

M at the 15th cycle indicating cleavage after V₁₇₇.

The 1st cycle can indicate cleavage after D₁₉₁, see Table 1.

R at the 4th and 13th cycle indicating cleavage after V₁₇₇.

R at the 2nd and 11th cycle indicating cleavage after Y₁₇₉.

V at the 2nd, 6th, and 13th cycle indicating cleavage after V₁₇₅, M₁₆₉ and presence of the N-terminus of the substrate, respectively. Note fragments beginning at 176 and 170 in Table 1.

Y at the 1st, 2nd, and 14th cycles indicating cleavage after V₁₇₅, V₁₇₇, and presence of the N-terminus of the substrate, respectively.

L at the 11th and 12th cycles indicating cleavage after V₁₇₇, and presence of the N-terminus of the substrate, respectively, is the interpretation most consistent with the other data. Comparing to the mass spectrometry results we see that L at the 2nd, 5th, and 9th cycles is consistent with cleavage after F₁₈₈, E₁₈₃ or M₁₆₉, and Y₁₇₉, respectively. See Table 1.

5 Epitope Identification

Fragments co-C-terminal with 8-10 amino acid long sequences predicted to bind HLA by the SYFPEITHI or NIH algorithms were chosen for further analysis. The digestion and prediction steps of the procedure can be usefully practiced in any order. Although the substrate peptide used in proteasomal digest described here was specifically designed to include a predicted HLA-A1 binding sequence, the actual products of digestion can be checked after the fact for actual or predicted binding to other MHC molecules. Selected results are shown in Table 2.

10 **Table 2. Predicted HLA binding by proteasomally generated fragments**

I. SEQ ID NO	II. PEPTIDE	HLA	SYFPEITHI	NIH
5 & (6)	(G)MPEGDLVYV	A*0201	17 (27)	(2605)
		B*0702	20	< 5
		B*5101	22	314
7 & (8)	(Q)GMPEGDLVY	A1	24 (26)	< 5
		A3	16 (18)	36
		B*2705	17	25
		B*5101	15	NP†
9	MPEGDLVY	A1	27 (15)	12
		A26	23 (17)	NP
10 & (11)	(P)EGDLVYVNY	A3	21	< 5
12	LVYVNYARTE	A26	(20)	NP
13 & (14)	(Y)VNYARTEDF	B*08	15	< 5
		B*2705	12	50
		A24	NP†	100
15	NYARTEDFF	Cw*0401	NP	120
16	YARTEDFF	B*08	16	< 5
17	RTEDFFKLE	A1	21	< 5
		A26	15	NP

†No prediction

HLA-A*0201 binding assay:

15 Binding of the candidate epitope PSMA₁₈₈₋₁₇₇, GMPEGDLVYV, (SEQ ID NO. 6) to HLA-A2.1 was assayed using a modification of the method of Stauss et al., (Proc Natl Acad Sci USA 89(17):7871-5 (1992)). Specifically, T2 cells, which express empty or unstable MHC molecules on their surface, were washed twice with Iscove's modified Dulbecco's medium (IMDM) and cultured overnight in serum-free AIM-V medium (Life Technologies, Inc., Rockville, MD)

supplemented with human β 2-microglobulin at $3\mu\text{g/ml}$ (Sigma, St. Louis, MO) and added peptide, at 800, 400, 200, 100, 50, 25, 12.5, and $6.25\mu\text{g/ml}$ in a 96-well flat-bottom plate at 3×10^5 cells/ $200\mu\text{l}$ /well. Peptide was mixed with the cells by repipeting before distributing to the plate (alternatively peptide can be added to individual wells), and the plate was rocked gently for 2 minutes. Incubation was in a 5% CO_2 incubator at 37°C . The next day the unbound peptide was removed by washing twice with serum free RPMI medium and a saturating amount of anti-class I HLA monoclonal antibody, fluorescein isothiocyanate (FITC)-conjugated anti-HLA A2, A28 (One Lambda, Canoga Park, CA) was added. After incubation for 30 minutes at 4°C , cells were washed 3 times with PBS supplemented with 0.5% BSA, 0.05%(w/v) sodium azide, pH 7.4-7.6 (staining buffer). (Alternatively W6/32 (Sigma) can be used as the anti-class I HLA monoclonal antibody the cells washed with staining buffer and then incubated with fluorescein isothiocyanate (FITC)-conjugated goat F(ab') antimouse-IgG (Sigma) for 30 min at 4°C and washed 3 times as before.) The cells were resuspended in 0.5 ml staining buffer. The analysis of surface HLA-A2.1 molecules stabilized by peptide binding was performed by flow cytometry using a FACScan (Becton Dickinson, San Jose, CA). If flow cytometry is not to be performed immediately the cells can be fixed by adding a quarter volume of 2% paraformaldehyde and storing in the dark at 4°C .

As seen in figure 2, this epitope exhibits significant binding at even lower concentrations than the positive control peptides. The Melan-A peptide used as a control in this assay (and throughout this disclosure), ELAGIGILTV (SEQ ID NO: 106), is actually a variant of the natural sequence (EAAGIGILTV; SEQ ID NO: 107) and exhibits a high affinity in this assay. The known A2.1 binder FLPSDYFPSV (HBV₁₈₋₂₇; SEQ ID NO: 107) was also used as a positive control. An HLA-B44 binding peptide, AEMGKYSFY (SEQ ID NO: 109), was used as a negative control. The fluorescence obtained from the negative control was similar to the signal obtained when no peptide was used in the assay. Positive and negative control peptides were chosen from Table 18.3.1 in *Current Protocols in Immunology* p. 18.3.2, John Wiley and Sons, New York, 1998.

Example 1.2

Cluster Analysis (PSMA₂₈₁₋₃₁₀).

Another peptide, RGIAEAVGLPSIPVHPIGYYDAQKLEKMG, PSMA₂₈₁₋₃₁₀ (SEQ ID NO. 18), containing an A1 epitope cluster from prostate specific membrane antigen, PSMA₂₈₃₋₃₀₇ (SEQ ID NO. 19), was synthesized using standard solid-phase F-moc chemistry on a 433A ABI Peptide synthesizer. After side chain deprotection and cleavage from the resin, peptide in ddH₂O was run on a reverse-phase preparative HPLC C18 column at following conditions: linear AB gradient (5% B/min) at a flow rate of 4 ml/min, where eluent A is 0.1% aqueous TFA and eluent B is 0.1% TFA in acetonitrile. A fraction at time 17.061 min containing the expected peptide as judged by mass spectrometry, was pooled and lyophilized. The peptide was then subjected to proteasome digestion and mass spectrum analysis essentially as described above. Prominent peaks from the mass spectra are summarized in Table 3.

Table 3. PSMA₂₈₁₋₃₁₀ Mass Peak Identification.

PEPTIDE	SEQUENCE	CALCULATED MASS (MH ⁺)
281-297	RGIAEAVGLPSIPVHPI*	1727.07
286-297	AVGLPSIPVHPI**	1200.46
287-297	VGLPSIPVHPI	1129.38
288-297	GLPSIPVHPI†	1030.25
298-310	GYDAQKLEKMG‡	1516.5
298-305	GYDAQKLS	958.05
281-305	RGIAEAVGLPSIPVHPIGYDAQKL	2666.12
281-307	RGIAEAVGLPSIPVHPIGYDAQKLE	2908.39
286-307	AVGLPSIPVHPIGYDAQKLE¶	2381.78
287-307	VGLPSIPVHPIGYDAQKLE	2310.70
288-307	GLPSIPVHPIGYDAQKLE#	2211.57
281-299	RGIAEAVGLPSIPVHPIGY	1947
286-299	AVGLPSIPVHPIGY	1420.69
287-299	VGLPSIPVHPIGY	1349.61
288-299	GLPSIPVHPIGY	1250.48
287-310	VGLPSIPVHPIGYDAQKLEKMG	2627.14
288-310	GLPSIPVHPIGYDAQKLEKMG	2528.01

Boldface sequences correspond to peptides predicted to bind to MHC, see Table 4.

*By mass alone this peak could also have been 296-310 or 288-303.

**By mass alone this peak could also have been 298-307. Combination of HPLC and mass spectrometry show that at some later time points this peak is a mixture of both species.

† By mass alone this peak could also have been 289-298.

‡ By mass alone this peak could also have been 281-295 or 294-306.

§ By mass alone this peak could also have been 297-303.

¶ By mass alone this peak could also have been 285-306.

By mass alone this peak could also have been 288-303.

None of these alternate assignments are supported N-terminal pool sequence analysis.

N-terminal Pool Sequence Analysis

One aliquot at one hour of the proteasomal digestion (see Example 3 part 3 above) was subjected to N-terminal amino acid sequence analysis by an ABI 473A Protein Sequencer (Applied Biosystems, Foster City, CA). Determination of the sites and efficiencies of cleavage was based on consideration of the sequence cycle, the repetitive yield of the protein sequencer, and the relative yields of amino acids unique in the analyzed sequence. That is if the unique (in the analyzed sequence) residue X appears only in the nth cycle a cleavage site exists n-1 residues before it in the N-terminal direction. In addition to helping resolve any ambiguity in the assignment of mass to sequences, these data also provide a more reliable indication of the relative yield of the various fragments than does mass spectrometry.

For PSMA₂₈₁₋₃₁₀ (SEQ ID NO. 18) this pool sequencing supports two major cleavage sites after V₂₈₇ and I₂₉₇ among other minor cleavage sites. Reviewing the results presented in Fig. 3 reveals the following:

S at the 4th and 11th cycles indicating cleavage after V₂₈₇ and presence of the N-terminus of the substrate, respectively.

H at the 8th cycle indicating cleavage after V₂₈₇. The lack of decay in peak height at positions 9 and 10 versus the drop in height present going from 10 to 11 can suggest cleavage after A₂₈₈ and E₂₈₅ as well, rather than the peaks representing latency in the sequencing reaction.

D at the 2nd, 4th, and 7th cycles indicating cleavages after Y₂₉₉, I₂₉₇, and V₂₉₄, respectively. This last cleavage is not observed in any of the fragments in Table 4 or in the alternate assignments in the notes below.

Q at the 6th cycle indicating cleavage after I₂₉₇.

M at the 10th and 12th cycle indicating cleavages after Y₂₉₉ and I₂₉₇, respectively.

Epitope Identification

Fragments co-C-terminal with 8-10 amino acid long sequences predicted to bind HLA by the SYFPEITHI or NIH algorithms were chosen for further study. The digestion and prediction steps of the procedure can be usefully practiced in any order. Although the substrate peptide used in proteasomal digest described here was specifically designed to include a predicted HLA-A1 binding sequence, the actual products of digestion can be checked after the fact for actual or predicted binding to other MHC molecules. Selected results are shown in Table 4.

Table 4.

Predicted HLA binding by proteasomally generated fragments: PSMA₂₈₁₋₃₁₀

III. SEQ ID NO.	IV. PEPTIDE	HLA	SYFPEITHI	NIH
20 & (21)	(G)LPSIPVHPI	A*0201	16 (24)	(24)
		B*0702/B7	23	12
		B*5101	24	572
		Cw*0401	NP†	20
22 & (23)	(P)IGYYDAQKL	A*0201	(16)	< 5
		A26	(20)	NP
		B*2705	16	25
		B*2709	15	NP
		B*5101	21	57
		Cw*0301	NP	24
24 & (25)	(P)SIPVHPIGY	A1	21 (27)	< 5
		A26	22	NP
		A3	16	< 5
		B*5101	16	NP
26	IPVHPIGY			
27	YYDAQKLE	A1	22	< 5

†No prediction

As seen in Table 4, N-terminal addition of authentic sequence to epitopes can often generate still useful, even better epitopes, for the same or different MHC restriction elements. Note for example the pairing of (G)LPSPVHPI with HLA-A*0201, where the 10-mer can be used as a vaccine useful with several MHC types by relying on N-terminal trimming to create the epitopes for HLA-B7, -B*5101, and Cw*0401.

5 **HLA-A*0201 binding assay:**

HLA-A*0201 binding studies were performed with PSMA₂₈₈₋₂₉₇, GLPSIPVHPI, (SEQ ID NO. 21) essentially as described in Example 1.1 above. As seen in figure 2, this epitope exhibits significant binding at even lower concentrations than the positive control peptides.

Example 1.3

10 **Cluster Analysis (PSMA₄₅₄₋₄₈₁).**

Another peptide, SSIEGNYTLRV DCTPLMYSLVHLTKEL, PSMA₄₅₄₋₄₈₁, (SEQ ID NO. 28) containing an epitope cluster from prostate specific membrane antigen, was synthesized by MPS (purity >95%) and subjected to proteasome digestion and mass spectrum analysis as described above. Prominent peaks from the mass spectra are summarized in Table 5.

15 **Table 5. PSMA₄₅₄₋₄₈₁ Mass Peak Identification.**

MS (measured)	PEAK	PEPTIDE	SEQUENCE	CALCULATED MASS (MH ⁺)
1238.5	454-464	SSIEGNYTLRV		1239.78
1768.38 ± 0.60	454-469	SSIEGNYTLRV DCTPL		1768.99
1899.8	454-470	SSIEGNYTLRV DCTPLM		1900.19
1097.63 ± 0.91	463-471	RVDCTPLMY		1098.32
2062.87 ± 0.68	454-471*	SSIEGNYTLRV DCTPLMY		2063.36
1153	472-481**	SLVHNLTKEL		1154.36
1449.93 ± 1.79	470-481	MYSLVHNLTKEL		1448.73

Boldface sequence correspond to peptides predicted to bind to MHC, see Table 6.

* On the basis of mass alone this peak could equally well be assigned to the peptide 455-472 however proteasomal removal of just the N-terminal amino acid is considered unlikely. If the issue were important it could be resolved by N-terminal sequencing.

**On the basis of mass this fragment might also represent 455-464.

Epitope Identification

Fragments co-C-terminal with 8-10 amino acid long sequences predicted to bind HLA by the SYFPEITHI or NIH algorithms were chosen for further study. The digestion and prediction steps of the procedure can be usefully practiced in any order. Although the substrate peptide used in proteasomal digest described here was specifically designed to include predicted HLA-A2.1 binding sequences, the actual products of digestion can be checked after the fact for actual or predicted binding to other MHC molecules. Selected results are shown in Table 6.

Table 6. Predicted HLA binding by proteasomally generated fragments

V. SEQ ID NO	VI. PEPTIDE	HLA	SYFPEITHI	NIH
29 & (30)	(S)IEGNYTLRV	A1	(19)	<5
31	EGNYTLRV	A*0201	16 (22)	<5
		B*5101	15	NP†
32 & (33)	(Y)TLRVDCTPL	A*0201	20 (18)	(5)
		A26	16 (18)	NP
		B7	14	40
		B8	23	<5
		B*2705	12	30
		Cw*0301	NP	(30)
34	LRVDCTPLM	B*2705	20	600
		B*2709	20	NP
35 & (36)	(L)RVDCTPLMY	A1	32 (22)	125 (13.5)
		A3	25	<5
		A26	22	NP
		B*2702	NP	(200)
		B*2705	13 (NP)	(1000)

†No prediction

As seen in Table 6, N-terminal addition of authentic sequence to epitopes can often generate still useful, even better epitopes, for the same or different MHC restriction elements. Note for example the pairing of (L)RVDCTPLMY (SEQ ID NOS 35 and (36)) with HLA-B*2702/5, where the 10-mer has substantial predicted halftimes of dissociation and the co-C-terminal 9-mer does not. Also note the case of SIEGNYTLRV (SEQ ID NO 30) a predicted HLA-A*0201 epitope which can be used as a vaccine useful with HLA-B*5101 by relying on N-terminal trimming to create the epitope.

HLA-A*0201 binding assay

HLA-A*0201 binding studies were preformed, essentially as described in Example 1.1 above, with PSMA₄₆₀₋₄₆₉ YTLRVDCTPL (SEQ ID NO.33). As seen in figure 4, this epitope was found to bind HLA-A2.1 to a similar extent as the known A2.1 binder FLPSDYFPSV (HBV₁₈₋₂₇; SEQ ID NO: 108) used as a positive control. Additionally, PSMA₄₆₁₋₄₆₉ (SEQ ID NO. 32) binds nearly as well.

ELISPOT analysis: PSMA₄₆₃₋₄₇₁ (SEQ ID NO. 35)

The wells of a nitrocellulose-backed microtiter plate were coated with capture antibody by incubating overnight at 4°C using 50 µl/well of 4µg/ml murine anti-human -IFN monoclonal antibody in coating buffer (35 mM sodium bicarbonate, 15 mM sodium carbonate, pH 9.5). Unbound antibody was removed by washing 4 times 5 min. with PBS. Unbound sites on the membrane then were blocked by adding 200µl/well of RPMI medium with 10% serum and incubating 1 hr. at room temperature. Antigen stimulated CD8⁺ T cells, in 1:3 serial dilutions, were seeded into the wells of the microtiter plate using 100µl/well, starting at 2x10⁵ cells/well. (Prior antigen stimulation was

essentially as described in Scheibenbogen, C. et al. *Int. J. Cancer* 71:932-936, 1997; which is incorporated herein by reference in its entirety.) PSMA₄₆₂₋₄₇₁ (SEQ ID NO. 36) was added to a final concentration of 10 µg/ml and IL-2 to 100 U/ml and the cells cultured at 37°C in a 5% CO₂, water-saturated atmosphere for 40 hrs. Following this incubation the plates were washed with 6 times 200 µl/well of PBS containing 0.05% Tween-20 (PBS-Tween). Detection antibody, 50 µl/well of 2g/ml biotinylated murine anti-human -IFN monoclonal antibody in PBS + 10% fetal calf serum, was added and the plate incubated at room temperature for 2 hrs. Unbound detection antibody was removed by washing with 4 times 200 µl of PBS-Tween. 100 µl of avidin-conjugated horseradish peroxidase (Pharmingen, San Diego, CA) was added to each well and incubated at room temperature for 1 hr. Unbound enzyme was removed by washing with 6 times 200 µl of PBS-Tween. Substrate was prepared by dissolving a 20 mg tablet of 3-amino 9-ethylcarbazole in 2.5 ml of N, N-dimethylformamide and adding that solution to 47.5 ml of 0.05 M phosphate-citrate buffer (pH 5.0). 25 µl of 30% H₂O₂ was added to the substrate solution immediately before distributing substrate at 100 µl/well and incubating the plate at room temperature. After color development (generally 15-30 min.), the reaction was stopped by washing the plate with water. The plate was air dried and the spots counted using a stereomicroscope.

Figure 5 shows the detection of PSMA₄₆₃₋₄₇₁ (SEQ ID NO. 35)-reactive HLA-A1⁺ CD8⁺ T cells previously generated in cultures of HLA-A1⁺ CD8⁺ T cells with autologous dendritic cells plus the peptide. No reactivity is detected from cultures without peptide (data not shown). In this case it can be seen that the peptide reactive T cells are present in the culture at a frequency between 1 in 2.2x10⁴ and 1 in 6.7x10⁴. That this is truly an HLA-A1-restricted response is demonstrated by the ability of anti-HLA-A1 monoclonal antibody to block -IFN production; see figure 6.

Example 1.4

Cluster Analysis (PSMA₆₅₃₋₆₈₇).

Another peptide, FDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFY PSMA₆₅₃₋₆₈₇, (SEQ ID NO. 37) containing an A2 epitope cluster from prostate specific membrane antigen, PSMA₆₆₀₋₆₈₁ (SEQ ID NO. 38), was synthesized by MPS (purity > 95%) and subjected to proteasome digestion and mass spectrum analysis as described above. Prominent peaks from the mass spectra are summarized in Table 7.

Table 7. PSMA₆₅₃₋₆₈₇ Mass Peak Identification.

MS PEAK (measured)	PEPTIDE	SEQUENCE	CALCULATED MASS (MH ⁺)
906.17±0.65	681-687**	LPDRPFY	908.05
1287.73±0.76	677-687**	DPLGLPDRPFY	1290.47
1400.3±1.79	676-687	IDPLGLPDRPFY	1403.63
1548.0±1.37	675-687	FIDPLGLPDRPFY	1550.80
1619.5±1.51	674-687**	AFIDPLGLPDRPFY	1621.88
1775.48±1.32	673-687*	RAFIDPLGLPDRPFY	1778.07
2440.2±1.3	653-672	FDKSNPIVLRMMNDQLMFLE	2442.93
1904.63±1.56	672-687*	ERAFIDPLGLPDRPFY	1907.19
2310.6±2.5	653-671	FDKSNPIVLRMMNDQLMFL	2313.82
2017.4±1.94	671-687	LERAFIDPLGLPDRPFY	2020.35
2197.43±1.78	653-670	FDKSNPIVLRMMNDQLMF	2200.66

Boldface sequence correspond to peptides predicted to bind to MHC, see Table 7.

* On the basis of mass alone this peak could equally well be assigned to a peptide beginning at 654, however proteasomal removal of just the N-terminal amino acid is considered unlikely. If the issue were important it could be resolved by N-terminal sequencing.

** On the basis of mass alone these peaks could have been assigned to internal fragments, but given the overall pattern of digestion it was considered unlikely.

Epitope Identification

Fragments co-C-terminal with 8-10 amino acid long sequences predicted to bind HLA by the SYFPEITHI or NIH algorithms were chosen for further study. The digestion and prediction steps of the procedure can be usefully practiced in any order. Although the substrate peptide used in proteasomal digest described here was specifically designed to include predicted HLA-A2.1 binding sequences, the actual products of digestion can be checked after the fact for actual or predicted binding to other MHC molecules. Selected results are shown in Table 8.

Table 8. Predicted HLA binding by proteasomally generated fragments

VII. SEQ ID NO	VIII. PEPTIDE	HLA	SYFPEITHI	NIH
39 & (40)	(R)MMNDQLMFL	A*0201	24 (23)	1360 (722)
		A*0205	NP†	71 (42)
		A26	15	NP
		B*2705	12	50
41	RMMNDQLMF	B*2705	17	75

†No prediction

As seen in Table 8, N-terminal addition of authentic sequence to epitopes can generate still useful, even better epitopes, for the same or different MHC restriction elements. Note for example the pairing of (R)MMNDQLMFL (SEQ ID NOS. 39 and (40)) with HLA-A*02, where the 10-mer retains substantial predicted binding potential.

HLA-A*0201 binding assay

HLA-A*0201 binding studies were performed, essentially as described in Example 1.1 above, with PSMA₆₈₃₋₆₇₁, (SEQ ID NO. 39) and PSMA₆₈₂₋₆₇₁, RMMNDQLMFL (SEQ NO. 67). As seen in figures 4, 7 and 8, this epitope exhibits significant binding at even lower concentrations than the positive control peptide (FLPSDYFPSV (HBV₁₈₋₂₇); SEQ ID NO. 108). Though not run in parallel, comparison to the controls suggests that PSMA₆₈₂₋₆₇₁ (which approaches the Melan A peptide in affinity) has the superior binding activity of these two PSMA peptides.

Example 2.

A multi-center clinical study is carried out using compositions as disclosed herein. The results of the study show the compositions to be useful and effective for debulking solid tumors and for generally inducing anti-angiogenic activity.

Example 3. Evaluation of a PSMA composition in the Xenotransplanted Human Vasculature ModelGeneration of target antigen-reactive CTL**A. *In vivo* immunization of mice.**

HHD1 transgenic A*0201 mice (Pascolo, S., et al. *J. Exp. Med.* 185:2043-2051, 1997) were anesthetized and injected subcutaneously at the base of the tail, avoiding lateral tail veins, using 100 μ l containing 100 nmol of PSMA₂₈₈₋₂₈₇ (SEQ ID NO. 21) and 20 μ g of a HTL epitope peptide in PBS emulsified with 50 μ l of IFA (incomplete Freund's adjuvant).

B. Preparation of stimulating cells (LPS blasts).

Using spleens from 2 naïve mice for each group of immunized mice, un-immunized mice were sacrificed and their carcasses placed in alcohol. Using sterile instruments, the top dermal layer of skin on the mouse's left side (lower mid-section) was cut through, exposing the peritoneum. The peritoneum was saturated with alcohol, and the spleen aseptically extracted. The spleens were placed in a petri dish with serum-free media. Splenocytes were isolated by using sterile plungers from 3 ml syringes to mash the spleens. Cells were collected in a 50 ml conical tubes in serum-free media, rinsing dish well. Cells were centrifuged (12000 rpm, 7 min) and washed one time with RPMI. Fresh spleen cells were resuspended to a concentration of 1×10^6 cells per ml in RPMI-10%FCS (fetal calf serum). 25g/ml lipopolysaccharide and 7 μ g/ml Dextran Sulfate were added. Cell were incubated for 3 days in T-75 flasks at 37°C, with 5% CO₂. Splenic blasts were collected in 50 ml tubes pelleted (12,000 rpm, 7 min) and resuspended to 3×10^7 /ml in RPMI. The blasts were pulsed with the priming peptide at 50 μ g/ml, RT 4hr. mitomycin C-treated at 25 μ g/ml, 37°C, 20 min and washed three times with DMEM.

C. *In vitro* stimulation.

Three days after LPS stimulation of the blast cells and the same day as peptide loading, the primed mice were sacrificed (at 14 days post immunization) to remove spleens as above. 3×10^6 splenocytes were co-cultured with 1×10^6 LPS blasts/well in 24-well plates at 37°C, with 5% CO₂ in DMEM media supplemented with 10% FCS, 5×10^{-5} M β (beta)-mercaptoethanol, 100 μ g/ml streptomycin and 100 IU/ml penicillin. Cultures were fed 5% (vol/vol) ConA

supernatant on day 3 and can be transferred on day 7. An aliquot of the CTL are also tested in a standard chromium release assay to ensure activity.

Implantation and Adoptive transfer

5 1×10^6 telomerase-transformed HDMEC in $10 \mu\text{l}$ of EGM-2-VM medium (Clonetics, San Diego, CA) are mixed with 0.5 ml of MATRIGEL (Becton Dickinson) on ice. The mixture is injected subcutaneously, through a 25 gauge needle, along the ventral midline of the thorax of SCID mice. One week later 1×10^7 T cells (target epitope-reactive or sham-immunized) in 0.2 ml are injected intravenously (alternatively they can be injected intraperitoneally).

Assessment (Micromorphometry)

10 At one and two weeks after transfer remove implants, fix in 10% buffered overnight, embed in paraffin, and section. For immunofluorescence detection of human microvessels using anti-human type IV collagen IgG and fluorescently-labeled secondary antibody, deparinize and retrieve antigen by microwaving thin sections 2x7 minutes in 10mM citric acid, pH 6.0. Vessel density is assessed as a function of the average number of positively stained annular structures observed in five separate, randomly selected 20x fields-of-view, from at least three sections per implant.

15 Example 4. A Fibronectin ED-B Vaccine in the HLA-transgenic Mouse Model

A. Establishment of tumor

M1 tumor cells grown in complete RPMI plus 10% serum were harvested and washed with PBS by centrifugation. The cells were suspended in PBS at 5×10^6 cells/ml and 0.5 ml of the suspension (early passage) was injected subcutaneously into the abdomen.

20 B. Vaccination

A nucleotide sequence encoding an HLA-A2-restricted fibronectin ED-B domain-derived housekeeping epitope, for example ED-B₂₉₋₃₈ (SEQ ID NO. 103), is inserted into an appropriate vaccine vector (e.g. pVAX1 (Invitrogen Inc, Carlsbad, CA) or one of the vectors described in U.S. Patent Application No. 09/561,572 entitled "EXPRESSION VECTORS ENCODING EPITOPES OF TARGET-ASSOCIATED ANTIGENS," filed on April 28, 2001. HHD-A2 mice are
25 injected intranodally in the inguinal lymph node with 0, 2, 10, 50, 100, and 200 μg of vector in PBS every other day over 8 days (4 injections) alternating sides for each injection (single dosage per mouse or group of mice). Injection series are started the day of tumor cell injection, at 2 weeks before, and at 4 and 10 weeks after.

C. Evaluation

30 At approximately 12 weeks after injection of tumor cells visible tumors are observed in the mice receiving the vehicle instead of the vaccine. Effectiveness of the vaccine is expressed as the proportion of vaccinated animals that fail to develop a tumor in the same time frame, the relative size of tumors at the same time point, the delay in time before tumors appear in the vaccinated animals, and the dose and number of composition cycles needed to inhibit or prevent the establishment of tumor.

D. Alternative schedule

The availability of more aggressive later passage M1 cells enables a more compressed experimental schedule. Instead mice are vaccinated on the day of tumor cell inoculation, 1 and 2 weeks before, and 3 or 4 days after injections of 1×10^6 cells. Effectiveness of vaccination is assessed at approximately 10 days after tumor cell inoculation.

E. Immunization with peptide

HHD-A2 mice were immunized with ED-B29-38 (SEQ ID NO. 103) in complete Freund's adjuvants and spleen cells were harvested and re-stimulated *in vitro* using standard methodology. The resulting CTL were able to specifically lyse peptide pulsed T2 cells, which are HLA-A2+ (Fig. 9).

Example 5. Epitopes and Epitope Clusters

Table 9 discloses epitopes and epitope clusters from PSMA and ED-B that can be useful in construction of compositions according to the present invention.

Table 9. SEQ ID NOS.*

SEQ ID NO	IDENTITY	SEQUENCE
1	PSMA protein	Accession number*: NP_004467
2	PSMA cDNA	Accession number: NM_004476
3	PSMA163-192	AFSPQGMPEGDLVYVNYARTEDFFKLERDM
4	PSMA 168-190	GMPEGDLVYVNYARTEDFFKLER
5	PSMA 169-177	MPPEGDLVYV
6	PSMA 168-177	GMPEGDLVYV
7	PSMA 168-176	GMPEGDLVY
8	PSMA 167-176	QGMPEGDLVY
9	PSMA 169-176	MPPEGDLVY
10	PSMA 171-179	EGDLVYVNY
11	PSMA 170-179	PEGDLVYVNY
12	PSMA 174-183	LVYVNYARTE
13	PSMA 177-185	VNYARTEDF
14	PSMA 176-185	YVNYARTEDF
15	PSMA 178-186	NYARTEDFF
16	PSMA 179-186	YARTEDFF
17	PSMA 181-189	RTEDFFKLE
18	PSMA 281-310	RGIAEAVGLPSIPVHPIGYYDAQKLEKMG
19	PSMA 283-307	IAEAVGLPSIPVHPIGYYDAQKLE
20	PSMA 289-297	LPSIPVHPI
21	PSMA 288-297	GLPSIPVHPI
22	PSMA 297-305	IGYYDAQKL
23	PSMA 296-305	PIGYDAQKL
24	PSMA 291-299	SIPVHPIGY
25	PSMA 290-299	PSIPVHPIGY

26	PSMA 292-299	IPVHPIGY
27	PSMA 299-307	YYDAQKLE
28	PSMA454-481	SSIEGNYTLRVDCTPLMYSLVHLTKEL
29	PSMA 456-464	IEGNYTLRV
30	PSMA 455-464	SIEGNYTLRV
31	PSMA 457-464	EGNYTLRV
32	PSMA 461-469	TLRVDCTPL
33	PSMA 460-469	YTLRVDCTPL
34	PSMA 462-470	LRVDCTPLM
35	PSMA 463-471	RVDCTPLMY
36	PSMA 462-471	LRVDCTPLMY
37	PSMA653-687	FDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFY
38	PSMA 660-681	VLRMMNDQLMFLERAFIDPLGL
39	PSMA 663-671	MMNDQLMFL
40	PSMA 662-671	RMMNDQLMFL
41	PSMA 662-670	RMMNDQLMF
42	PSMA 4-12	LLHETDSAV
43	PSMA 13-21	ATARRPRWL
44	PSMA 53-61	TPKHNMKAF
45	PSMA 64-73	ELKAENIKKF
46	PSMA 69-77	NIKKFLH'NF
47	PSMA 68-77	ENIKKFLH'NF
48	PSMA 220-228	AGAKGVILY
49	PSMA 468-477	PLMYSLVHNL
50	PSMA 469-477	LMYSLVHNL
51	PSMA 463-471	RVDCTPLMY
52	PSMA 465-473	DCTPLMYSL
53	PSMA 507-515	SGMPRISKL
54	PSMA 506-515	FSGMPRISKL
55	PSMA 211-218	GNKVKNAQ
56	PSMA 202-209	IARYGKVF
57	PSMA 217-225	AQLAGAKGV
58	PSMA 207-215	KVFRGNKVK
59	PSMA 211-219	GNKVKNAQL
60	PSMA 269-277	TPGYPANEY
61	PSMA 268-277	LTPGYPANEY
62	PSMA 271-279	GYPANEYAY
63	PSMA 270-279	PGYPANEYAY
64	PSMA 266-274	DPLTPGYPA
65	PSMA 492-500	SLYESWTKK
66	PSMA 491-500	KSLYESWTKK
67	PSMA 486-494	EGFEGKSLY

68	PSMA 485-494	DEGFEGKSLY
69	PSMA 498-506	TKKSPSPEF
70	PSMA 497-506	WTKKSPSPEF
71	PSMA 492-501	SLYESWTKKS
72	PSMA 725-732	WGEVKRQI
73	PSMA 724-732	AWGEVKRQI
74	PSMA 723-732	KAWGEVKRQI
75	PSMA 723-730	KAWGEVKR
76	PSMA 722-730	SKAWGEVKR
77	PSMA 731-739	QIYVAAFTV
78	PSMA 733-741	YVAAFTVQA
79	PSMA 725-733	WGEVKRQIY
80	PSMA 727-735	EVKRQIYVA
81	PSMA 738-746	TVQAAAETL
82	PSMA 737-746	FTVQAAAETL
83	PSMA 729-737	KRQIYVAAF
84	PSMA 721-729	PSKAWGEVK
85	PSMA 723-731	KAWGEVKRQ
86	PSMA 100-108	WKEFGLDSV
87	PSMA 99-108	QWKEFGLDSV
88	PSMA 102-111	EFGLDSELA
89	ED-B domain of Fibronectin	EVPQLTDLFSVDITDSSIGLRWTPLNSTIIGYRI TVVAAGEGIPIFEDFVDSSVGYTGTGLEPGID YDISVITLINGGESAPTTLTQQT
90	ED-B domain of Fibronectin with flanking sequence from Fibronectin	CTFDNLSPGLEYNVSVYTVKDDKESVPISDTIIP EVPQLTDLFSVDITDSSIGLRWTPLNSTIIGYRI TVVAAGEGIPIFEDFVDSSVGYTGTGLEPGID YDISVITLINGGESAPTTLTQQT AVPPPTDLRFTNIGPDTMRVTW
91	ED-B domain of Fibronectin cds	Accession number: X07717
92	ED-B 4'-5	TIIEVPQL
93	ED-B 5'-5	DTIIEVPQL
94	ED-B 1-10	EVPQLTDLF
95	ED-B 23-30	TPLNSTI
96	ED-B 18-25	IGLRWTPL
97	ED-B 17-25	SIGLRWTPL
98	ED-B 25-33	LNSSTIIGY
99	ED-B 24-33	PLNSSTIIGY
100	ED-B 23-31	TPLNSTII
101	ED-B 31-38	IIGYRITVV
102	ED-B 30-38	IIGYRITVV
103	ED-B 29-38	TIIGYRITVV
104	ED-B 31-39	IIGYRITVVA

105	ED-B 30-39	IIGYRITVVA
106	Melan-A 26-35 _{A>1}	ELAGIGILTV
107	Melan-A 26-35	EAAGIGILTV
108	HBV 18-27	FLPSDYFPSV
109	HLA-B44 binder	AEMGKYSFY

¹ This H was reported as Y in the SWISSPROT database.

*Any of SEQ ID NOS. 5-17, 20-27, 29-36, 39-88, and 92-105 can be useful as epitopes in the various embodiments of the invention. Any of SEQ ID NOS. 3, 4, 18, 19, 28, 37, 38, 89 and 90 can be useful as sequences containing epitopes or epitope clusters, as described in various embodiments of the invention.

5

**All accession numbers used here and throughout can be accessed through the NCBI databases, for example, through the Entrez seek and retrieval system on the world wide web.

10

PSMA

LOCUS NM_004476 2653 bp mRNA PRI 01-NOV-2000

DEFINITION Homo sapiens folate hydrolase (prostate-specific membrane antigen)
1 (FOLH1), mRNA.

ACCESSION NM_004476

15

VERSION NM_004476.1 GI:4758397

KEYWORDS .

SOURCE human.

ORGANISM Homo sapiens

20

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 2653)

AUTHORS Israeli,R.S., Powell,C.T., Fair,W.R. and Heston,W.D.

TITLE Molecular cloning of a complementary DNA encoding a
prostate-specific membrane antigen

25

JOURNAL Cancer Res. 53 (2), 227-230 (1993)

MEDLINE 93113576

REFERENCE 2 (bases 1 to 2653)

AUTHORS Rinker-Schaeffer CW, Hawkins AL, Su SL, Israeli RS, Griffin CA,
Isaacs JT and Heston WD.

30

TITLE Localization and physical mapping of the prostate-specific membrane
antigen (PSM) gene to human chromosome 11

JOURNAL Genomics 30 (1), 105-108 (1995)

MEDLINE 96129312

PUBMED 8595888

35

REFERENCE 3 (bases 1 to 2653)

AUTHORS O'Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT,
Zandvliet D, Russell PJ, Molloy PL, Nowak NJ, Shows TB, Mullins C,
Vonder Haar RA, Fair WR and Heston WD.

TITLE Mapping, genomic organization and promoter analysis of the human
prostate-specific membrane antigen gene

40

JOURNAL Biochim. Biophys. Acta 1443 (1-2), 113-127 (1998)

MEDLINE 99057588

PUBMED 9838072

REFERENCE 4 (bases 1 to 2653)

45

AUTHORS Maraj BH, Leek JP, Karayi M, Ali M, Lench NJ and Markham AF.

TITLE Detailed genetic mapping around a putative prostate-specific
 membrane antigen locus on human chromosome 11p11.2
 JOURNAL Cytogenet. Cell Genet. 81 (1), 3-9 (1998)
 MEDLINE 98358137
 5 PUBMED 9691167
 COMMENT PROVISIONAL REFSEQ: This record has not yet been subject to final
 NCBI review. The reference sequence was derived from M99487.1.
 FEATURES Location/Qualifiers
 source 1..2653
 10 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="11"
 /map="11p11.2"
 /sex="male"
 15 /cell_line="LNCaP-ATCC"
 /cell_type="prostate"
 /tissue_type="prostatic carcinoma metastatic lymph node"
 /tissue_lib="LNCaP cDNA of Ron Israeli"
 gene 1..2653
 20 /gene="FOLH1"
 /note="FOLH; PSM; PSMA"
 /db_xref="LocusID:2346"
 /db_xref="MIM:600934"
 CDS 262..2514
 25 /gene="FOLH1"
 /note="folate hydrolase 1 (prostate-specific membrane
 antigen)"
 /codon_start=1
 /db_xref="LocusID:2346"
 30 /db_xref="MIM:600934"
 /evidence=experimental
 /product="folate hydrolase (prostate-specific membrane
 antigen) 1"
 /protein_id="NP_004467.1"
 35 /db_xref="GI:4758398"
 /translation="MWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLGWFIK
 SSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKE
 FGLDSVELAHYDVLLSYPNKTHPNYISIHEDGNEIFNTSLFEPPIPGYENVSDIVPP
 FSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVARIYGVFRGNKVKNQAQ
 40 LAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNI LNAGDPLTPGYANE
 YAYRRGIAEAVGLPSIPVHPIGYYDAQKLEKMGGSAPPDSSWRGSLKVPYNVGPFT
 GNFSTQKV KMHISTNEVTRIYNVIGTLRGAVEPDYVILGGHRDSWVFGGIDPSGA
 AVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLOERGVAYI
 NADSSIEGNYTLRVDCTPLMYSLVHNLTKEKSPDEGFEGKSLYESWTKKSPSPEFSG
 45 MPRISKLGSGNDFEVFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETVELVEKFY
 DPMFKYHLTVAQVRGGMVFE LANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKT
 YSVSFDLSFAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLP
 DRPFYRHVIYAPSSH NKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAFTVQ
 AAAETLSEVA" (SEQ ID NO. 1)
 50 misc_feature 778..1029
 /note="PA; Region: PA domain"
 BASE COUNT 782 a 524 c 640 g 707 t
 ORIGIN

1 ctcaaaaggg gccggatttc cttctcctgg aggcagatgt tgcctctctc tctcgctcgg
 61 attggttcag tgcactctag aaacactgct gtggtggaga aactggacc caggctcggg
 121 gcgaattcca gcctgcaggg ctgataagcg aggcattagt gagattgaga gagactttac
 181 cccgccgtgg tgggtggagg gcgcgcagta gagcagcagc acaggcgagg gtcccgggag
 5 241 gccggctctg ctgcgcgcca gatgtggaat ctcttcacg aaaccgactc ggctgtggcc
 301 accgcgcgcc gccgcgcgct gctgtgcgct ggggcgctgg tgctggcggg tggcttcttt
 361 ctctcgggct tcctcttcgg gtggtttata aaatcctcca atgaagctac taacattact
 421 ccaaagcata atatgaaagc atttttggat gaattgaaag ctgagaacat caagaagttc
 481 ttatataatt ttacacagat accacattta gcaggaacag aacaaaactt tcagcttgca
 10 541 aagcaaatc aatcccagtg gaaagaattt ggctgggatt ctgttgagct agcacattat
 601 gatgtctgt tgcctaccc aaataagact catcccaact acatctcaat aattaatgaa
 661 gatgaaatg agattttcaa cacatcatta ttgaaccac ctctccagg atatgaaat
 721 ttttcggata ttgtaccacc ttctcgtct tctctcctc aaggaaatgcc agaggcgat
 781 ctatgtatg ttaactatgc acgaactgaa gactcttta aattggaacg ggacatgaaa
 15 841 atcaattgct ctgggaaaaa tgaattgcc agatattgga aagttttcag aggaaataag
 901 gttaaaaaat cccagctggc aggggccaac ggagtcattc tctactcca cctgctgac
 961 tactttgctc ctggggtgaa gtcctatcca gatggttga atctcctgg aggtgtgtc
 1021 cagcgtggaa atactctaaa tctgaatggt gcaggagacc ctctcacacc aggttaccac
 1081 gcaaatgaat atgcttatag gcgtggaatt gcaggagctg ttggtctcc aagtattcct
 20 1141 gttcatcaa ttgatacta tgatgcacag aagctcctag aaaaaatggg tggctcagca
 1201 ccaccagata gcagctggag aggaagtctc aaagtgcctt acaatgttg accctggctt
 1261 actggaactt ttctacaca aaaagtcaag atgcacatcc actctacca tgaagtaca
 1321 agaatttaca atgtgatagg tactctcaga ggagcagtg aaccagacag atatgtcatt
 1381 ctgggaggtc accgggactc atgggtgttt ggtgtattg accctcagag tggagcagct
 25 1441 gttgttcag aaattgtgag gagctttgga acactgaaaa aggaagggtg gagacctaga
 1501 agaacaattt tgtttgcaag ctgggatgca gaagaatttg gtctcttg tctactgag
 1561 tgggcagagg agaattcaag actcctcaa gagcgtggcg tggcttatat taatgtgac
 1621 tcatctatag aaggaaacta cactctgaga gtgattgta caccgctgat gtacagctg
 1681 gtacacaacc taacaaaaga gctgaaaagc cctgatgaag gctttgaagg caaatctctt
 30 1741 tatgaaagt ggactaaaaa aagtccttcc ccagagtcca gtggcatgcc caggataagc
 1801 aaattgggat ctggaatga tttgagggtg ttctccaac gacttgaat tgcttcaggc
 1861 agagcacggt atactaaaaa ttgggaaca aacaaattca gcggctatcc actgtatcac
 1921 agtgctctat aaacatatga gttggtgaa aagttttatg atccaatgtt taaatatcac
 1981 ctactgttg cccaggttcg aggggggatg gtgtttgagc tagccaattc catagtgtc
 35 2041 ccttttgatt gtcgagatta tgctgtagt ttaagaaagt atgctgaca aatctacagt
 2101 atttctatga aacatccaca ggaatgaag acatacagtg tatcatttga ttcactttt
 2161 tctgcagtaa agaattttac agaaatgct tccaagtcca gtgagagact ccaggacttt
 2221 gacaaaagca acccaatagt attaagaatg atgaatgac aactcatgtt tctggaaaga
 2281 gcattttatg atccattagg gttaccagac aggcctttt ataggcatgt catctatgct
 40 2341 ccaagcagcc acaacaagta tgcaggggag tcattcccag gaattatga tgctctgtt
 2401 gatattgaaa gcaaatgga ccttccaag gcctggggag aagtgaagag acagatttat
 2461 gttgcagcct tcacagtga ggcagctgca gagacttga gtgaagtagc ctaaggaggat
 2521 tctttagaga atccgtattg aatttgtgt gtatgtcact cagaaagaat cgtaatgggt
 2581 atattgataa attttaaaat tggatatatt gaaataaagt tgaatattat atataaaaaa
 45 2641 aaaaaaaaaa aaa (SEQ ID NO. 2)

ED-B domain of Fibronectin

LOCUS HSFIBEDB 2823 bp DNA linear PRI 09-AUG-1999

50 DEFINITION Human fibronectin gene ED-B region.

ACCESSION X07717
 VERSION X07717.1 GI:31406
 KEYWORDS alternate splicing; fibronectin.
 SOURCE human.
 5 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2823)
 AUTHORS Paoletta,G., Henchcliffe,C., Sebastio,G. and Baralle,F.E.
 10 TITLE Sequence analysis and *in vivo* expression show that alternative
 splicing of ED-B and ED-A regions of the human fibronectin gene are
 independent events
 JOURNAL Nucleic Acids Res. 16 (8), 3545-3557 (1988)
 MEDLINE 88233940
 15 FEATURES Location/Qualifiers
 source 1..2823
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="MA10"
 20 exon 1..104
 /number=1
 /product="fibronectin"
 CDS join(< 2..104,1375..1647,2758..> 2823)
 /codon_start=1
 25 /product="fibronectin"
 /protein_id="CAB52437.1"
 /db_xref="GI:5725425"
 /translation="CTFDNLSPGLEYNVSVYTVKDDKESVPISDTIPEVPQLTDLSF
 VDITDSSIGLRWTPLNSSSTIIGYRITVVAAGEGIPFEDFVSSVGYTGTGLEPGID
 30 YDISVITLINGGESAPTTLTQQTAVPPPTDLRFTNIGPDTMRVTW" (SEQ ID NO. 90)
 intron 105..1374
 /number=1
 exon 1375..1647
 /note="ED-B exon"
 35 /number=2

/product="fibronectin"

intron 1648..2757

/number=2

exon 2758..2823

5

/number=3

/product="fibronectin"

BASE COUNT 824 a 556 c 528 g 915 t

ORIGIN

1 ctgcactttt gataacctga gtcccgccct ggagtacaat gtcagtgttt acactgtcaa
 10 61 ggatgacaag gaaagtgtcc ctatctctga taccatcatc ccaggttaata gaaaataagc
 121 tgctatcctg agagtgcacat tccaataaga gtggggatta gcactttaat cccagatgc
 181 ttaagggtgt caactatatt tgggatttaa ttccgatctc ccagctgcac ttccaaaac
 241 caagaagtca aagcagcgat ttggacaaaa tgcttgctgt taacactgct ttactgtctg
 301 tgcttactg ggatgtctgt tgttcagcgt agtatgtaat ggagtggcag ccattggcttt
 15 361 aactctgtat tgtctgctca catggaagta tgactaaaac actgtcacgt gtctgtactc
 421 agtactgata ggctcaaagt aatatggtaa atgcatccca tcagtacatt tctgcccgat
 481 tttaacaacc atatcaattt ccaacagctg cctatttcct ctgacagttt caaatccttc
 541 tttttgaaaa ttggatttta aaaaaaagtt aagtaaaagt cacaccttca ggggtgttct
 601 ttctgtggc ctgaaagac aacattgcaa aggcctgtcc taaggatagg cttgtttgtc
 20 661 cattgggtta taacataatg aaagcattgg acagatcgtg tcccccttg gactcttcag
 721 tagaatgctt ttactaacgc taattacatg ttttgattat gaatgaacct aaaatagtgg
 781 caatggcctt aacctaggcc tgtctttcct cagcctgaat gtgcttttga atggcacatt
 841 tcacaccata cattcataat gcattagcgt tatggccatg atgttgcat gagttttgta
 901 tgggagaaaa aaaatcaatt tatcaccat ttattatttt ttccggtgtg tcatgcaagc
 25 961 ttattttcta ctaaaacagt ttggaatta ttaaaagcat tgctgatact tacttcagat
 1021 attatgtcta ggctctaaga atggtttcga calcctaacc agccatatga ttttaggaa
 1081 tctgaacagt tcaaattgta cctttaagg atgttttcaa aatgtaaaaa atatatatat
 1141 atatatatat tccctaaaag aatattcctg ttatttcttc tagggaagca aactgttcat
 1201 gatgcttagg aagtcttttc agagaattta aaacagattg catattacca tcattgcttt
 30 1261 aacattccac caattttact actagtaacc tgatatacac tgctttattt tttcctcttt
 1321 ttttccctct attttccttt tgctcctccc tccctttgct ttgtaactca atagaggtgc
 1381 cccaactcac tgacctaaagc ttgttgata taaccgattc aagcatcggc ctgagggtga
 1441 ccccgctaaa ctcttcacc attattgggt accgcatcac agtagttgcg gcaggagaag
 1501 gtatccctat ttttgaagat ttgtggact cctcagtagg atactacaca gtcacagggc
 35 1561 tggagccggg cattgactat gatatcagcg ttatcactct cattaatggc ggcgagagtg

1621 cccctactac actgacacaa caaacgggtg aattttgaaa acttctgcgt ttgagacata
 1681 gatggtgttg catgctgcca ccagttactc cggttaaata tggatgttc atgggggaag
 1741 tcagcaattg gccaaagatt cagatagggt gaattggggg gataaggaat caaatgcac
 1801 tgctaaactg attggagaaa aacacatgca atatcttcag tacactctca tttaaaccac
 5 1861 aagtagatat aaagcctaga gaaatacaga tgtctgctct gttaaatata aaatagcaaa
 1921 tgttcattca attgaagac ctagaatfff tcttctaaa taccaaacc gaataccaaa
 1981 ttgcgaagt accaattgat aagaatata caccaaaatg taccatcatg ctcttccttc
 2041 tacccttga taaactctac catgctcctt cttttagctt aaaaacccat caaaatttag
 2101 ggtagagtgg atgggcattg ttttgaggta ggagaaaagt aaacttgga ccattctagg
 10 2161 ttttgtgct gtcactagg aaagaacac ctcttaacc acagtctggg gacaagcatg
 2221 caacatttta aaggttctct gctgtgcatg ggaaaagaaa catgctgaga accaatttgc
 2281 atgaacatgt tcactgttaa gtagaattca ctgaatggaa ctgtagctct agatatctca
 2341 catgggggga agtttaggac cctctgtct tttgtctgt gtgcatgtat tctttgtaa
 2401 agtactgcta tgtttctctt tgctgtgtgg caactaagc ctcttcggcc tgggataaaa
 15 2461 taactgcag tggattaat aatgtacata aagtcaacat attgaaagt agattaaaat
 2521 cttttttaa tatatcaatg atggcaaaaa ggtaaaggg ggcctaacag tactgtgtgt
 2581 agtgtttat ttttaacagt agtacactat aacttaaat agacttagat tagactgttt
 2641 gcatgattat gattctgttt cctttatgca tgaatattg attttacctt tccagctact
 2701 tcgttagctt taattttaa atacattaac tgagtctcc tctgttgc aaaccagctg
 20 2761 ttctctccc cactgacctg cgattacca acattgttcc agacaccatg cgtgtcacct
 2821 ggg (SEQ ID NO. 91)

//

WHAT IS CLAIMED IS:

1. A method of evaluating cell-mediated immunity comprising the steps of:
implanting vascular cells into an immunodeficient mammal;
 establishing an immune response in the mammal; and
 5 *assaying a characteristic to determine cell-mediated immunity in the mammal.*
2. The method of claim 1, wherein the cell-mediated immunity is directed against a neovasculature antigen.
3. The method of claim 2, wherein the neovasculature antigen is preferentially expressed by tumor-associated neovasculature.
- 10 4. The method of claim 2, wherein the neovasculature antigen is prostate specific membrane antigen (PSMA) or vascular endothelial growth factor receptor 2 (VEGFR2).
5. The method of claim 1, wherein the establishing step is achieved by adoptive transfer of T-cells to the mammal.
6. The method of claim 1, wherein the establishing step is achieved by contacting the mammal with
 15 an antigen.
7. The method of claim 1, wherein the cell-mediated immunity is mediated by cytotoxic T lymphocytes.
8. The method of claim 1, wherein the vascular cells are vascular endothelial cells.
9. The method of claim 8, wherein the endothelial cells are HDMEC.
- 20 10. The method of claim 8, wherein the endothelial cells are telomerase-transformed endothelial cells.
11. The method of claim 1, wherein the immunodeficient mammal is a mouse.
12. The method of claim 10, wherein the immunodeficient mouse is a SCID mouse.
13. The method of claim 1, wherein the characterizing step comprises assessing a parameter selected
 25 from the group consisting of vessel formation, vessel destruction, vessel density, and proportion of vessels carrying blood of the host mammal.
14. The method of claim 1, further comprising the step of *implanting tumor cells or tumor tissue in the mouse.*
15. The method of claim 14, wherein the characterizing step comprises assessing a parameter selected
 30 from the group consisting of tumor presence, tumor growth, tumor size, rapidity of tumor appearance, dose of vaccine required to inhibit or prevent tumor establishment, tumor vascularization, and a proportion of necrotic tissue within the tumor.
16. The method of claim 1, further comprising the steps of:
 35 *providing a first population of mammals and a second populations of mammals;*
 establishing cell-mediated immunity in the first population;
 differentially establishing cell-mediated immunity in the second population; and

comparing a result obtained from the first population of mammals to a result obtained from the second population of mammals.

17. The method of claim 16, wherein the cell-mediated immunity of the first population is selected from the group consisting of naïve immunity and immunity to an irrelevant epitope.

5 18. A method of evaluating cell-mediated immunity, comprising the steps of:
implanting or injecting MHC-transgenic tumor cells into an MHC-transgenic mammal;
establishing an immune response in the mammal; and
assaying a characteristic to determine cell-mediated immunity in the mammal.

19. The method of claim 18, wherein the MHC-transgenic mammal is an HLA-transgenic mammal.

10 20. The method of claim 19, wherein the HLA-transgenic mammal is an HLA-A2 transgenic mammal.

21. The method of claim 18, wherein the mammal is a mouse.

22. The method of claim 18, wherein the cell-mediated immunity is established by vaccination.

23. The method of claim 22, wherein the vaccination takes place prior to, concurrent with, or subsequent to transfer of the tumor cells.

15 24. The method of claim 18, wherein the cell-mediated immunity is mediated by cytotoxic T lymphocytes.

25. The method of claim 18, wherein the neovasculature antigen is preferentially expressed by tumor-associated neovasculature.

26. The method of claim 18, wherein the neovasculature antigen is also a tumor-associated antigen.

20 27. The method of claim 26, wherein the antigen is the ED-B domain of fibronectin.

28. The method of claim 18, wherein the characterizing step comprises assessing a parameter selected from the group consisting of tumor presence, tumor growth, tumor size, rapidity of tumor appearance, dose of vaccine required to inhibit or prevent tumor establishment, tumor vascularization, and a proportion of necrotic tissue within the tumor.

25 29. The method of claim 18, further comprising the steps of:
providing a first population of mammals and a second populations of mammals;
establishing cell-mediated immunity in the first population;
differentially establishing cell-mediated immunity in the second population; and
comparing a result obtained from the first population of mammals to a result obtained from the
30 second population of mammals.

30. The method of claim 29, wherein the cell-mediated immunity of the first population is selected from the group consisting of naïve immunity and immunity to an irrelevant epitope.

31. A method of treating neoplastic disease comprising the step of immunizing a mammal to induce a cellular immune response directed against an antigen differentially expressed by tumor-associated neovasculature.

35 32. The method of claim 31, wherein the differentially expressed antigen is a protein.

33. The method of claim 32, wherein the protein is prostate specific membrane antigen.
34. The method of claim 31, wherein the antigen is the ED-B domain of fibronectin.
35. The method of claim 32, wherein immunization is carried out with at least one peptide derived from the sequence of said protein.
- 5 36. The method of claim 32, wherein immunization is carried out with a nucleic acid capable of conferring expression of said protein or peptides.
37. The method of claim 36, wherein the at least one peptide comprises a housekeeping epitope.
38. The method of claim 37, wherein the at least one peptide is co-C-terminal with the housekeeping epitope.
- 10 39. The method of claim 37, further comprising at least one additional peptide wherein the at least one additional peptide comprises an immune epitope.
40. The method of claim 31, comprising an additional step wherein the mammal is treated with an anti-tumor therapy active directly against cancerous cells.
41. The method of claim 40, wherein the anti-tumor therapy is immunization against a tumor-associated antigen.
- 15 42. The method of claim 31, wherein the cellular immune response comprises a CTL response.
43. An immunogenic composition comprising at least one immunogen corresponding to an antigen expressed by tumor-associated neovasculature, wherein the composition can induce a cellular immune response.
44. The composition of claim 43, wherein the immunogen is not associated with a cell conspecific with the recipient.
- 20 45. The composition of claim 43, wherein the antigen is a protein.
46. The composition of claim 45, wherein the protein is prostate specific membrane antigen.
47. The composition of claim 43, wherein the antigen is the ED-B domain of fibronectin.
48. The composition of claim 43, wherein the immunogen comprises at least one peptide.
- 25 49. The composition of claim 43, comprising a nucleic acid capable of conferring expression of said antigen, and wherein said antigen is a protein or a peptide.
50. The composition of claim 49, comprising at least one peptide comprising a housekeeping epitope.
51. The composition of claim 50, wherein the at least one peptide is co-C-terminal with the housekeeping epitope.
- 30 52. The composition of claim 50, additionally comprising at least one peptide comprising an immune epitope.
53. The composition of claim 43, additionally comprising at least one immunogen corresponding to a tumor-associated antigen.
54. The composition of claim 43, wherein the cellular immune response comprises a CTL response.
- 35 55. A method of anti-tumor vaccine design comprising the steps of:

identifying an antigen differentially expressed by tumor-associated neovasculature; and
incorporating a component of the antigen into a vaccine.

56. The method of claim 55, wherein the component is a polypeptide fragment of the antigen.

57. The method of claim 55, wherein the component is a nucleic acid encoding the antigen or a
5 fragment of the antigen.

58. A method of making a research model, comprising implanting a vascular cell and a tumor cell into an
immunodeficient mammal, wherein said tumor cell is implanted adjacent to said vascular cell.

59. The method of claim 58, wherein said vascular cell is a vascular endothelial cell.

60. The method of claim 59, wherein said vascular endothelial cell is HDMEC.


10 61. The method of claim 59, wherein said vascular endothelial cell is telomerase-transformed.

62. The method of claim 58, wherein said immunodeficient mammal is a mouse.

63. The method of claim 62, wherein said mouse is a SCID mouse.


64. A research model comprising an immunodeficient mammal, the mammal comprising an implanted
vascular cell and an implanted tumor cell, wherein said vascular cell and said tumor cell are implanted adjacent to one
15 another.

Pool sequencing of PSMA_163–192 Digested for 60 min by proteasome




2/11

FIG. 1B



Pool sequencing of PSMA_163-192 Digested for 60 min by proteasome

3/11





Pool sequencing of PSMA₁₆₃₋₁₉₂ Digested for 60 min by proteasome

FIG. 1C

SUBSTITUTE SHEET (RULE 26)


FIG. 2






6/11

FIG. 4
Comparison of Peptides Binding
Affinity to HLA A2
by Binding Assay




7/11

Autologous DC Present A1 Peptide to CD8 T cell

*FIG. 5*


8/11

Secretion of IFN γ Was Blocked by Anti-A1 Antibody

*FIG. 6*


9/11

FIG. 7
Comparison of Peptides Binding Affinity
to HLA A2 by Binding Assay




10/11

FIG. 8
Comparison of Peptides Binding Affinity
to HLA A2 by Binding Assay



11/11

FIG. 9 ED-B 29-38 specific lysis by CTL from peptide immunized HHD-A2 mice



SEQUENCE LISTING

<110> CTL IMMUNOTHERAPIES CORP.
SIMARD, John, J.L.
DIAMOND, David, C.

<120> ANTI-NEOVASCULATURE PREPARATIONS FOR
CANCER

<130> CTLIMM.015VPC

<150> US 60/274,063

<151> 2001-03-07

<160> 109

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 750

<212> PRT

<213> Homo sapien

<400> 1

Met	Trp	Asn	Leu	Leu	His	Glu	Thr	Asp	Ser	Ala	Val	Ala	Thr	Ala	Arg
1				5				10						15	
Arg	Pro	Arg	Trp	Leu	Cys	Ala	Gly	Ala	Leu	Val	Leu	Ala	Gly	Gly	Phe
			20					25					30		
Phe	Leu	Leu	Gly	Phe	Leu	Phe	Gly	Trp	Phe	Ile	Lys	Ser	Ser	Asn	Glu
		35					40					45			
Ala	Thr	Asn	Ile	Thr	Pro	Lys	His	Asn	Met	Lys	Ala	Phe	Leu	Asp	Glu
	50					55					60				
Leu	Lys	Ala	Glu	Asn	Ile	Lys	Lys	Phe	Leu	Tyr	Asn	Phe	Thr	Gln	Ile
65				70					75					80	
Pro	His	Leu	Ala	Gly	Thr	Glu	Gln	Asn	Phe	Gln	Leu	Ala	Lys	Gln	Ile
				85					90					95	
Gln	Ser	Gln	Trp	Lys	Glu	Phe	Gly	Leu	Asp	Ser	Val	Glu	Leu	Ala	His
			100					105					110		
Tyr	Asp	Val	Leu	Leu	Ser	Tyr	Pro	Asn	Lys	Thr	His	Pro	Asn	Tyr	Ile
		115					120					125			
Ser	Ile	Ile	Asn	Glu	Asp	Gly	Asn	Glu	Ile	Phe	Asn	Thr	Ser	Leu	Phe
	130					135					140				
Glu	Pro	Pro	Pro	Pro	Gly	Tyr	Glu	Asn	Val	Ser	Asp	Ile	Val	Pro	Pro
145				150						155				160	
Phe	Ser	Ala	Phe	Ser	Pro	Gln	Gly	Met	Pro	Glu	Gly	Asp	Leu	Val	Tyr
			165						170					175	
Val	Asn	Tyr	Ala	Arg	Thr	Glu	Asp	Phe	Phe	Lys	Leu	Glu	Arg	Asp	Met
			180					185					190		
Lys	Ile	Asn	Cys	Ser	Gly	Lys	Ile	Val	Ile	Ala	Arg	Tyr	Gly	Lys	Val
		195				200						205			
Phe	Arg	Gly	Asn	Lys	Val	Lys	Asn	Ala	Gln	Leu	Ala	Gly	Ala	Lys	Gly
	210					215					220				
Val	Ile	Leu	Tyr	Ser	Asp	Pro	Ala	Asp	Tyr	Phe	Ala	Pro	Gly	Val	Lys
225					230					235				240	

Ser Tyr Pro Asp Gly Trp Asn Leu Pro Gly Gly Gly Val Gln Asn Gly
 245 250 255
 Asn Ile Leu Asn Leu Asn Gly Ala Gly Asp Pro Leu Thr Pro Gly Tyr
 260 265 270
 Pro Ala Asn Glu Tyr Ala Tyr Arg Arg Gly Ile Ala Glu Ala Val Gly
 275 280 285
 Leu Pro Ser Ile Pro Val His Pro Ile Gly Tyr Tyr Asp Ala Gln Lys
 290 295 300
 Leu Leu Glu Lys Met Gly Gly Ser Ala Pro Pro Asp Ser Ser Trp Arg
 305 310 315 320
 Gly Ser Leu Lys Val Pro Tyr Asn Val Gly Pro Gly Phe Thr Gly Asn
 325 330 335
 Phe Ser Thr Gln Lys Val Lys Met His Ile His Ser Thr Asn Glu Val
 340 345 350
 Thr Arg Ile Tyr Asn Val Ile Gly Thr Leu Arg Gly Ala Val Glu Pro
 355 360 365
 Asp Arg Tyr Val Ile Leu Gly Gly His Arg Asp Ser Trp Val Phe Gly
 370 375 380
 Gly Ile Asp Pro Gln Ser Gly Ala Ala Val Val His Glu Ile Val Arg
 385 390 395 400
 Ser Phe Gly Thr Leu Lys Lys Glu Gly Trp Arg Pro Arg Arg Thr Ile
 405 410 415
 Leu Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly Leu Leu Gly Ser Thr
 420 425 430
 Glu Trp Ala Glu Glu Asn Ser Arg Leu Leu Gln Glu Arg Gly Val Ala
 435 440 445
 Tyr Ile Asn Ala Asp Ser Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val
 450 455 460
 Asp Cys Thr Pro Leu Met Tyr Ser Leu Val His Asn Leu Thr Lys Glu
 465 470 475 480
 Leu Lys Ser Pro Asp Glu Gly Phe Glu Gly Lys Ser Leu Tyr Glu Ser
 485 490 495
 Trp Thr Lys Lys Ser Pro Ser Pro Glu Phe Ser Gly Met Pro Arg Ile
 500 505 510
 Ser Lys Leu Gly Ser Gly Asn Asp Phe Glu Val Phe Phe Gln Arg Leu
 515 520 525
 Gly Ile Ala Ser Gly Arg Ala Arg Tyr Thr Lys Asn Trp Glu Thr Asn
 530 535 540
 Lys Phe Ser Gly Tyr Pro Leu Tyr His Ser Val Tyr Glu Thr Tyr Glu
 545 550 555 560
 Leu Val Glu Lys Phe Tyr Asp Pro Met Phe Lys Tyr His Leu Thr Val
 565 570 575
 Ala Gln Val Arg Gly Gly Met Val Phe Glu Leu Ala Asn Ser Ile Val
 580 585 590
 Leu Pro Phe Asp Cys Arg Asp Tyr Ala Val Val Leu Arg Lys Tyr Ala
 595 600 605
 Asp Lys Ile Tyr Ser Ile Ser Met Lys His Pro Gln Glu Met Lys Thr
 610 615 620
 Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr
 625 630 635 640
 Glu Ile Ala Ser Lys Phe Ser Glu Arg Leu Gln Asp Phe Asp Lys Ser
 645 650 655
 Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln Leu Met Phe Leu Glu
 660 665 670
 Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg Pro Phe Tyr Arg

675	680	685
His Val Ile Tyr Ala Pro Ser Ser His Asn Lys Tyr Ala Gly Glu Ser		
690	695	700
Phe Pro Gly Ile Tyr Asp Ala Leu Phe Asp Ile Glu Ser Lys Val Asp		
705	710	715
Pro Ser Lys Ala Trp Gly Glu Val Lys Arg Gln Ile Tyr Val Ala Ala		
725	730	735
Phe Thr Val Gln Ala Ala Ala Glu Thr Leu Ser Glu Val Ala		
740	745	750

<210> 2
 <211> 2653
 <212> DNA
 <213> Homo sapien

<400> 2

```

ctcaaaaggg gccggatttc cttctcctgg aggcagatgt tgcctctctc tctcgctcgg 60
attggttcag tgcactctag aaacactgct gtggtggaga aactggaccc caggtctgga 120
gcgaattcca gcctgcaggg ctgataagcg aggcattagt gagattgaga gagactttac 180
cccgccgtgg tggttggagg gcgcgcagta ggcagcagc acaggcgagg gtccccggag 240
gccggctctg ctgcgcgcca gatgtggaat ctccctcacg aaaccgactc ggctgtggcc 300
accgcgcgcc gccgcgcctg gctgtgcgct ggggcgctgg tgctggcggg tggcttcttt 360
ctcctcggct tcctcttcgg gtggtttata aaatcctcca atgaagctac taacattact 420
ccaaagcata atatgaaagc atttttggat gaattgaaag ctgagaacat caagaagttc 480
ttatataaatt ttacacagat accacattta gcaggaacag aacaaaactt tcagcttgca 540
aagcaaattc aatcccagtg gaaagaattt ggcttgatt ctggtgagct agcacattat 600
gatgtcctgt tgtcctaccc aaataagact catcccaact acatctcaat aattaatgaa 660
gatggaaatg agattttcaa cacatcatta tttgaaccac ctctccagg atatgaaaat 720
gtttcggata ttgtaccacc tttcagtgtc ttctctctc aaggaatgcc agagggcgat 780
ctagtgtatg ttaactatgc acgaactgaa gacttcttta aattggaacg ggacatgaaa 840
atcaattgct ctgggaaaaat tgtaattgcc agatatggga aagttttcag aggaaataag 900
gttaaaaaatg ccagctggc aggggccaaa ggagtcattc tctactccga ccctgctgac 960
tactttgtct ctggggtgaa gtccatatcca gatgggttga atcttctctg aggtggtgtc 1020
cagcgtggaa atatactaaa tctgaatggt gcaggagacc ctctcacacc aggttaccac 1080
gcaaatgaat atgcttatag gcgttgaatt gcagaggctg ttggtcttcc aagtattcct 1140
gttcatccaa ttggatacta tgatgcacag aagctcctag aaaaaatggg tggctcagca 1200
ccaccagata gcagctggag aggaagtctc aaagtgcctt acaatgttgg acctggcttt 1260
actggaaact tttctacaca aaaagtcaag atgcacatcc actctaccaa tgaagtgaca 1320
agaatttaca atgtgatagg tactctcaga ggagcagtgg aaccagacag atatgtcatt 1380
ctgggagggt accgggactc atgggtgttt ggtggtattg accctcagag tggagcagct 1440
gttggttcag aaattgtgag gagcttttga aactgaaaa aggaagggtg gagacctaga 1500
agaacaattt tgtttgcaag ctgggatgca gaagaatttg gtcttcttgg ttctactgag 1560
tgggcagagg agaattcaag actccttcaa gagcgtggcg tggcttatat taatgttgac 1620
tcatctatag aaggaaacta cactctgaga gttgattgta caccgctgat gtacagcttg 1680
gtacacaacc taacaaaaga gctgaaaagc cctgatgaag gctttgaagg caaatctctt 1740
tatgaaagtt ggactaaaaa agtccttcc ccagagttca gtggcatgcc caggataagc 1800
aaattgggat ctggaaatga ttttgagggt ttcttccaac gacttggaat tgcttcaggc 1860
agagcacggt atactaaaaa ttgggaaaca aacaaattca gcggctatcc actgtatcac 1920
agtgtctatg aaacatatga gttggtggaa aagttttatg atccaatgtt taaatatcac 1980
ctcactgtgg ccagggttcg aggagggatg gtgtttgagc tagccaattc catagtgtc 2040
ccttttgatt gtcgagatta tgctgtagtt ttaagaaagt atgtgacaa aatctacagt 2100
atttctatga aacatccaca ggaaatgaag acatacagt tatcatttga ttacttttt 2160
tctgcagtaa agaattttac agaaattgct tccaagttca gtgagagact ccaggacttt 2220
gacaaaagca acccaatagt attaagaatg atgaatgatc aactcatgtt tctggaaaag 2280

```

```

gcattttattg atccattagg gttaccagac aggccttttt atattgattg cacttatgct 2340
ccaagcagcc acaacaagta tgcaggggag tcattcccag gaatttatga tgctctgttt 2400
gatattgaaa gcaaagtgga cccttccaag gcctggggag aagtgaagag acagatttat 2460
gttgcagcct tcacagtgca ggcagctgca gagactttga gtgaagtagc ctaagaggat 2520
tcttttagaga atccgtattg aatttgtgtg gtatgtcact cagaaagaat cgtaatgggt 2580
atattgataa atttttaa at ttggtatattt gaaataaagt tgaatattat atataaaaaa 2640
aaaaaaaaa aaa 2653

```

<210> 3
 <211> 30
 <212> PRT
 <213> Homo sapien

<400> 3
 Ala Phe Ser Pro Gln Gly Met Pro Glu Gly Asp Leu Val Tyr Val Asn
 1 5 10 15
 Tyr Ala Arg Thr Glu Asp Phe Phe Lys Leu Glu Arg Asp Met
 20 25 30

<210> 4
 <211> 23
 <212> PRT
 <213> Homo sapien

<400> 4
 Gly Met Pro Glu Gly Asp Leu Val Tyr Val Asn Tyr Ala Arg Thr Glu
 1 5 10 15
 Asp Phe Phe Lys Leu Glu Arg
 20

<210> 5
 <211> 9
 <212> PRT
 <213> Homo sapien

<400> 5
 Met Pro Glu Gly Asp Leu Val Tyr Val
 1 5

<210> 6
 <211> 10
 <212> PRT
 <213> Homo sapien

<400> 6
 Gly Met Pro Glu Gly Asp Leu Val Tyr Val
 1 5 10

<210> 7
 <211> 9
 <212> PRT

<213> Homo sapien

<400> 7

Gly Met Pro Glu Gly Asp Leu Val Tyr
1 5

<210> 8

<211> 10

<212> PRT

<213> Homo sapien

<400> 8

Gln Gly Met Pro Glu Gly Asp Leu Val Tyr
1 5 10

<210> 9

<211> 8

<212> PRT

<213> Homo sapien

<400> 9

Met Pro Glu Gly Asp Leu Val Tyr
1 5

<210> 10

<211> 9

<212> PRT

<213> Homo sapien

<400> 10

Glu Gly Asp Leu Val Tyr Val Asn Tyr
1 5

<210> 11

<211> 10

<212> PRT

<213> Homo sapien

<400> 11

Pro Glu Gly Asp Leu Val Tyr Val Asn Tyr
1 5 10

<210> 12

<211> 10

<212> PRT

<213> Homo sapien

<400> 12

Leu Val Tyr Val Asn Tyr Ala Arg Thr Glu
1 5 10

<210> 13
<211> 9
<212> PRT
<213> Homo sapien

<400> 13
Val Asn Tyr Ala Arg Thr Glu Asp Phe
1 5

<210> 14
<211> 10
<212> PRT
<213> Homo sapien

<400> 14
Tyr Val Asn Tyr Ala Arg Thr Glu Asp Phe
1 5 10

<210> 15
<211> 9
<212> PRT
<213> Homo sapien

<400> 15
Asn Tyr Ala Arg Thr Glu Asp Phe Phe
1 5

<210> 16
<211> 8
<212> PRT
<213> Homo sapien

<400> 16
Tyr Ala Arg Thr Glu Asp Phe Phe
1 5

<210> 17
<211> 9
<212> PRT
<213> Homo sapien

<400> 17
Arg Thr Glu Asp Phe Phe Lys Leu Glu
1 5

<210> 18
<211> 30
<212> PRT

<213> Homo sapien

<400> 18

Arg Gly Ile Ala Glu Ala Val Gly Leu Pro Ser Ile Pro Val His Pro
1 5 10 15
Ile Gly Tyr Tyr Asp Ala Gln Lys Leu Leu Glu Lys Met Gly
20 25 30

<210> 19

<211> 25

<212> PRT

<213> Homo sapien

<400> 19

Ile Ala Glu Ala Val Gly Leu Pro Ser Ile Pro Val His Pro Ile Gly
1 5 10 15
Tyr Tyr Asp Ala Gln Lys Leu Leu Glu
20 25

<210> 20

<211> 9

<212> PRT

<213> Homo sapien

<400> 20

Leu Pro Ser Ile Pro Val His Pro Ile
1 5

<210> 21

<211> 10

<212> PRT

<213> Homo sapien

<400> 21

Gly Leu Pro Ser Ile Pro Val His Pro Ile
1 5 10

<210> 22

<211> 9

<212> PRT

<213> Homo sapien

<400> 22

Ile Gly Tyr Tyr Asp Ala Gln Lys Leu
1 5

<210> 23

<211> 10

<212> PRT

<213> Homo sapien

<400> 23
Pro Ile Gly Tyr Tyr Asp Ala Gln Lys Leu
1 5 10

<210> 24
<211> 9
<212> PRT
<213> Homo sapien

<400> 24
Ser Ile Pro Val His Pro Ile Gly Tyr
1 5

<210> 25
<211> 10
<212> PRT
<213> Homo sapien

<400> 25
Pro Ser Ile Pro Val His Pro Ile Gly Tyr
1 5 10

<210> 26
<211> 8
<212> PRT
<213> Homo sapien

<400> 26
Ile Pro Val His Pro Ile Gly Tyr
1 5

<210> 27
<211> 9
<212> PRT
<213> Homo sapien

<400> 27
Tyr Tyr Asp Ala Gln Lys Leu Leu Glu
1 5

<210> 28
<211> 27
<212> PRT
<213> Homo sapien

<400> 28
Ser Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val Asp Cys Thr Pro Leu
1 5 10 15
Met Tyr Ser Leu Val His Leu Thr Lys Glu Leu

<210> 29
<211> 9
<212> PRT
<213> Homo sapien

<400> 29
Ile Glu Gly Asn Tyr Thr Leu Arg Val
1 5

<210> 30
<211> 10
<212> PRT
<213> Homo sapien

<400> 30
Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val
1 5 10

<210> 31
<211> 8
<212> PRT
<213> Homo sapien

<400> 31
Glu Gly Asn Tyr Thr Leu Arg Val
1 5

<210> 32
<211> 9
<212> PRT
<213> Homo sapien

<400> 32
Thr Leu Arg Val Asp Cys Thr Pro Leu
1 5

<210> 33
<211> 10
<212> PRT
<213> Homo sapien

<400> 33
Tyr Thr Leu Arg Val Asp Cys Thr Pro Leu
1 5 10

<210> 34
<211> 9

<212> PRT
 <213> Homo sapien

<400> 34
 Leu Arg Val Asp Cys Thr Pro Leu Met
 1 5

<210> 35
 <211> 9
 <212> PRT
 <213> Homo sapien

<400> 35
 Arg Val Asp Cys Thr Pro Leu Met Tyr
 1 5

<210> 36
 <211> 10
 <212> PRT
 <213> Homo sapien

<400> 36
 Leu Arg Val Asp Cys Thr Pro Leu Met Tyr
 1 5 10

<210> 37
 <211> 35
 <212> PRT
 <213> Homo sapien

<400> 37
 Phe Asp Lys Ser Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln Leu
 1 5 10 15
 Met Phe Leu Glu Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg
 20 25 30
 Pro Phe Tyr
 35

<210> 38
 <211> 22
 <212> PRT
 <213> Homo sapien

<400> 38
 Val Leu Arg Met Met Asn Asp Gln Leu Met Phe Leu Glu Arg Ala Phe
 1 5 10 15
 Ile Asp Pro Leu Gly Leu
 20

<210> 39

<211> 9
<212> PRT
<213> Homo sapien

<400> 39
Met Met Asn Asp Gln Leu Met Phe Leu
1 5

<210> 40
<211> 10
<212> PRT
<213> Homo sapien

<400> 40
Arg Met Met Asn Asp Gln Leu Met Phe Leu
1 5 10

<210> 41
<211> 9
<212> PRT
<213> Homo sapien

<400> 41
Arg Met Met Asn Asp Gln Leu Met Phe
1 5

<210> 42
<211> 9
<212> PRT
<213> Homo sapien

<400> 42
Leu Leu His Glu Thr Asp Ser Ala Val
1 5

<210> 43
<211> 9
<212> PRT
<213> Homo sapien

<400> 43
Ala Thr Ala Arg Arg Pro Arg Trp Leu
1 5

<210> 44
<211> 9
<212> PRT
<213> Homo sapien

<400> 44

Thr Pro Lys His Asn Met Lys Ala Phe
1 5

<210> 45
<211> 10
<212> PRT
<213> Homo sapien

<400> 45
Glu Leu Lys Ala Glu Asn Ile Lys Lys Phe
1 5 10

<210> 46
<211> 9
<212> PRT
<213> Homo sapien

<220>
<221> VARIANT
<222> (7)...(7)
<223> Xaa = His or Tyr

<400> 46
Asn Ile Lys Lys Phe Leu Xaa Asn Phe
1 5

<210> 47
<211> 10
<212> PRT
<213> Homo sapien

<220>
<221> VARIANT
<222> (8)...(8)
<223> Xaa = His or Tyr

<400> 47
Glu Asn Ile Lys Lys Phe Leu Xaa Asn Phe
1 5 10

<210> 48
<211> 9
<212> PRT
<213> Homo sapien

<400> 48
Ala Gly Ala Lys Gly Val Ile Leu Tyr
1 5

<210> 49

<211> 10
<212> PRT
<213> Homo sapien

<400> 49
Pro Leu Met Tyr Ser Leu Val His Asn Leu
1 5 10

<210> 50
<211> 9
<212> PRT
<213> Homo sapien

<400> 50
Leu Met Tyr Ser Leu Val His Asn Leu
1 5

<210> 51
<211> 9
<212> PRT
<213> Homo sapien

<400> 51
Arg Val Asp Cys Thr Pro Leu Met Tyr
1 5

<210> 52
<211> 9
<212> PRT
<213> Homo sapien

<400> 52
Asp Cys Thr Pro Leu Met Tyr Ser Leu
1 5

<210> 53
<211> 9
<212> PRT
<213> Homo sapien

<400> 53
Ser Gly Met Pro Arg Ile Ser Lys Leu
1 5

<210> 54
<211> 10
<212> PRT
<213> Homo sapien

<400> 54

Phe Ser Gly Met Pro Arg Ile Ser Lys Leu
1 5 10

<210> 55
<211> 8
<212> PRT
<213> Homo sapien

<400> 55
Gly Asn Lys Val Lys Asn Ala Gln
1 5

<210> 56
<211> 8
<212> PRT
<213> Homo sapien

<400> 56
Ile Ala Arg Tyr Gly Lys Val Phe
1 5

<210> 57
<211> 9
<212> PRT
<213> Homo sapien

<400> 57
Ala Gln Leu Ala Gly Ala Lys Gly Val
1 5

<210> 58
<211> 9
<212> PRT
<213> Homo sapien

<400> 58
Lys Val Phe Arg Gly Asn Lys Val Lys
1 5

<210> 59
<211> 9
<212> PRT
<213> Homo sapien

<400> 59
Gly Asn Lys Val Lys Asn Ala Gln Leu
1 5

<210> 60

<211> 9
<212> PRT
<213> Homo sapien

<400> 60
Thr Pro Gly Tyr Pro Ala Asn Glu Tyr
1 5

<210> 61
<211> 10
<212> PRT
<213> Homo sapien

<400> 61
Leu Thr Pro Gly Tyr Pro Ala Asn Glu Tyr
1 5 10

<210> 62
<211> 9
<212> PRT
<213> Homo sapien

<400> 62
Gly Tyr Pro Ala Asn Glu Tyr Ala Tyr
1 5

<210> 63
<211> 10
<212> PRT
<213> Homo sapien

<400> 63
Pro Gly Tyr Pro Ala Asn Glu Tyr Ala Tyr
1 5 10

<210> 64
<211> 9
<212> PRT
<213> Homo sapien

<400> 64
Asp Pro Leu Thr Pro Gly Tyr Pro Ala
1 5

<210> 65
<211> 9
<212> PRT
<213> Homo sapien

<400> 65

Ser Leu Tyr Glu Ser Trp Thr Lys Lys
1 5

<210> 66
<211> 10
<212> PRT
<213> Homo sapien

<400> 66
Lys Ser Leu Tyr Glu Ser Trp Thr Lys Lys
1 5 10

<210> 67
<211> 9
<212> PRT
<213> Homo sapien

<400> 67
Glu Gly Phe Glu Gly Lys Ser Leu Tyr
1 5

<210> 68
<211> 10
<212> PRT
<213> Homo sapien

<400> 68
Asp Glu Gly Phe Glu Gly Lys Ser Leu Tyr
1 5 10

<210> 69
<211> 9
<212> PRT
<213> Homo sapien

<400> 69
Thr Lys Lys Ser Pro Ser Pro Glu Phe
1 5

<210> 70
<211> 10
<212> PRT
<213> Homo sapien

<400> 70
Trp Thr Lys Lys Ser Pro Ser Pro Glu Phe
1 5 10

<210> 71

<211> 10
<212> PRT
<213> Homo sapien

<400> 71
Ser Leu Tyr Glu Ser Trp Thr Lys Lys Ser
1 5 10

<210> 72
<211> 8
<212> PRT
<213> Homo sapien

<400> 72
Trp Gly Glu Val Lys Arg Gln Ile
1 5

<210> 73
<211> 9
<212> PRT
<213> Homo sapien

<400> 73
Ala Trp Gly Glu Val Lys Arg Gln Ile
1 5

<210> 74
<211> 10
<212> PRT
<213> Homo sapien

<400> 74
Lys Ala Trp Gly Glu Val Lys Arg Gln Ile
1 5 10

<210> 75
<211> 8
<212> PRT
<213> Homo sapien

<400> 75
Lys Ala Trp Gly Glu Val Lys Arg
1 5

<210> 76
<211> 9
<212> PRT
<213> Homo sapien

<400> 76

Ser Lys Ala Trp Gly Glu Val Lys Arg
1 5

<210> 77
<211> 9
<212> PRT
<213> Homo sapien

<400> 77
Gln Ile Tyr Val Ala Ala Phe Thr Val
1 5

<210> 78
<211> 9
<212> PRT
<213> Homo sapien

<400> 78
Tyr Val Ala Ala Phe Thr Val Gln Ala
1 5

<210> 79
<211> 9
<212> PRT
<213> Homo sapien

<400> 79
Trp Gly Glu Val Lys Arg Gln Ile Tyr
1 5

<210> 80
<211> 9
<212> PRT
<213> Homo sapien

<400> 80
Glu Val Lys Arg Gln Ile Tyr Val Ala
1 5

<210> 81
<211> 9
<212> PRT
<213> Homo sapien

<400> 81
Thr Val Gln Ala Ala Ala Glu Thr Leu
1 5

<210> 82

<211> 10
<212> PRT
<213> Homo sapien

<400> 82
Phe Thr Val Gln Ala Ala Ala Glu Thr Leu
1 5 10

<210> 83
<211> 9
<212> PRT
<213> Homo sapien

<400> 83
Lys Arg Gln Ile Tyr Val Ala Ala Phe
1 5

<210> 84
<211> 9
<212> PRT
<213> Homo sapien

<400> 84
Pro Ser Lys Ala Trp Gly Glu Val Lys
1 5

<210> 85
<211> 9
<212> PRT
<213> Homo sapien

<400> 85
Lys Ala Trp Gly Glu Val Lys Arg Gln
1 5

<210> 86
<211> 9
<212> PRT
<213> Homo sapien

<400> 86
Trp Lys Glu Phe Gly Leu Asp Ser Val
1 5

<210> 87
<211> 10
<212> PRT
<213> Homo sapien

<400> 87

Gln Trp Lys Glu Phe Gly Leu Asp Ser Val
 1 5 10

<210> 88
 <211> 10
 <212> PRT
 <213> Homo sapien

<400> 88
 Glu Phe Gly Leu Asp Ser Val Glu Leu Ala
 1 5 10

<210> 89
 <211> 91
 <212> PRT
 <213> Homo sapien

<400> 89
 Glu Val Pro Gln Leu Thr Asp Leu Ser Phe Val Asp Ile Thr Asp Ser
 1 5 10 15
 Ser Ile Gly Leu Arg Trp Thr Pro Leu Asn Ser Ser Thr Ile Ile Gly
 20 25 30
 Tyr Arg Ile Thr Val Val Ala Ala Gly Glu Gly Ile Pro Ile Phe Glu
 35 40 45
 Asp Phe Val Asp Ser Ser Val Gly Tyr Tyr Thr Val Thr Gly Leu Glu
 50 55 60
 Pro Gly Ile Asp Tyr Asp Ile Ser Val Ile Thr Leu Ile Asn Gly Gly
 65 70 75 80
 Glu Ser Ala Pro Thr Thr Leu Thr Gln Gln Thr
 85 90

<210> 90
 <211> 147
 <212> PRT
 <213> Homo sapien

<400> 90
 Cys Thr Phe Asp Asn Leu Ser Pro Gly Leu Glu Tyr Asn Val Ser Val
 1 5 10 15
 Tyr Thr Val Lys Asp Asp Lys Glu Ser Val Pro Ile Ser Asp Thr Ile
 20 25 30
 Ile Pro Glu Val Pro Gln Leu Thr Asp Leu Ser Phe Val Asp Ile Thr
 35 40 45
 Asp Ser Ser Ile Gly Leu Arg Trp Thr Pro Leu Asn Ser Ser Thr Ile
 50 55 60
 Ile Gly Tyr Arg Ile Thr Val Val Ala Ala Gly Glu Gly Ile Pro Ile
 65 70 75 80
 Phe Glu Asp Phe Val Asp Ser Ser Val Gly Tyr Tyr Thr Val Thr Gly
 85 90 95
 Leu Glu Pro Gly Ile Asp Tyr Asp Ile Ser Val Ile Thr Leu Ile Asn
 100 105 110
 Gly Gly Glu Ser Ala Pro Thr Thr Leu Thr Gln Gln Thr Ala Val Pro

115 120 125
 Pro Pro Thr Asp Leu Arg Phe Thr Asn Ile Gly Pro Asp Thr Met Arg
 130 135 140
 Val Thr Trp
 145

<210> 91
 <211> 2823
 <212> DNA
 <213> Homo sapien

<400> 91
 ctgcactttt gataacctga gtcccggcct ggagtacaat gtcagtgttt acactgtcaa 60
 ggatgacaag gaaagtgtcc ctatctctga taccatcatc ccaggtaata gaaaataagc 120
 tgctatcctg agagtgcacat tccaataaga gtggggatta gcatcttaat cccagatgc 180
 ttaagggtgt caactatatt tgggatttaa ttccgatctc ccagctgcac tttccaaaac 240
 caagaagtca aagcagcgat ttggacaaaa tgcttgctgt taacactgct ttactgtctg 300
 tgcttcactg ggatgctgtg tggtgcagcg agtatgtaat ggagtggcag ccatggcttt 360
 aactctgtat tgtctgtcga catggaagta tgactaaaac actgtcacgt gtctgtactc 420
 agtactgata ggctcaaagt aatatggtaa atgcatccca tcagtacatt tctgcccgat 480
 tttacaatcc atatcaattt ccaacagctg cctatttcat cttgcagttt caaatccttc 540
 tttttgaaaa ttggatttta aaaaaaagtt aagtaaaagt cacaccttca gggttgttct 600
 ttcttgtggc cttgaaagac aacattgcaa aggcctgtcc taaggatagg cttgtttgtc 660
 cattgggtta taacataatg aaagcattgg acagatcgtg tcccccttg gactcttcag 720
 tagaatgctt ttactaacgc taattacatg ttttgattat gaatgaacct aaaatagtgg 780
 caatggcctt aacctaggcc tgtctttcct cagcctgaat gtgcttttga atggcacatt 840
 tcacaccata cattcataat gcattagcgt tatggccatg atgttgtcat gaggtttcta 900
 tgggagaaaa aaaatcaatt tatcaccat ttattatttt ttccggttgt tcatgcaagc 960
 ttattttcta ctaaacagtt tttggaatta ttaaaagcat tgctgatact tacttcagat 1020
 attatgtcta ggctctaaga atgggtttcga catcctaaac agccatatga tttttaggaa 1080
 tctgaacagt tcaaattgta ccctttaagg atgttttcaa aatgtaaaaa atatatatat 1140
 atatatatat tccctaaaag aatattcctg tttattcttc tagggaagca aactgttcat 1200
 gatgcttagg aagtcttttc agagaattta aaacagattg catattacca tcattgcttt 1260
 aacattccac caattttact actagtaacc tgatatacac tgctttattt tttcctcttc 1320
 ttttccctct ttttcccttt tgccctcccc tccctttgct ttgtaactca atagaggtgc 1380
 cccaactcac tgacctaaagc tttgttgata taaccgattc aagcatcggc ctgaggtgga 1440
 ccccgctaaa ctcttccacc attattgggt accgcatcac agtagttgct gcaggagaag 1500
 gtatccctat ttttgaagat tttgtggact cctcagtagg atactacaca gtcacagggc 1560
 tggagccggg cattgactat gatatcagcg ttatcactct cattaatggc ggcgagagt 1620
 cccctactac actgacacaa caaacgggtg aattttgaaa acttctgcgt ttgagacata 1680
 gatgggtgtg catgctgcca ccagttactc cggttaaata tggatgtttc atgggggaag 1740
 tcagcaattg gccaaagatt cagataggtg gaattggggg gataaggaaat caaatgcatc 1800
 tgctaaactg attggagaaa aacacatgca atattcttcag tacactctca tttaaaccac 1860
 aagtagatat aaagcctaga gaaatacaga tgtctgtctc gttaaataata aaatagcaaa 1920
 tgttcattca atttgaagac ctagaatttt tcttctttaa taccaaacac gaataccaaa 1980
 ttgcgtaagt accaattgat aagaatata caccaaaatg taccatcatg ctcttcttc 2040
 taccctttga taaactctac catgctcctt cttttagctt aaaaacccat caaaatttag 2100
 ggtagagtgg atgggcattg ttttgaggta ggagaaaagt aaacttggga ccattctagg 2160
 ttttgttgcgt gtcactagggt aaagaaacac ctctttaacc acagtctggg gacaagcatg 2220
 caacatttta aaggttctct gctgtgcatg ggaaaagaaa catgctgaga accaatttgc 2280
 atgaacatgt tcaattgtaa gtagaattca ctgaatggaa ctgtagctct agatatctca 2340
 catgggggga agtttaggac cctcttctct ttttgtctgt gtgcatgtat ttctttgtaa 2400
 agtactgcta tgtttctctt tgctgtgtgg caacttaagc ctcttcggcc tgggataaaa 2460
 taatctgcag tgggtattaat aatgtacata aagtcaacat atttgaaagt agattaaaaat 2520

```

cttttttaaa tatatcaatg atggcaaaaa ggtaaaggg ggctaacag tactgtgtgt 2580
agtgttttat ttttaacagt agtacactat aacttaaaat agacttagat tagactgttt 2640
gcatgattat gattctgttt cctttatgca tgaaatattg attttacett tccagctact 2700
tcgttagctt taattttaaa atacattaac tgagtcttcc ttcttggtcg aaaccagctg 2760
ttcctcctcc cactgacctg cgattcacca acattgggtcc agacaccatg cgtgtcacct 2820
ggg 2823

```

<210> 92

<211> 9

<212> PRT

<213> Homo sapien

<400> 92

Thr Ile Ile Pro Glu Val Pro Gln Leu

1

5

<210> 93

<211> 10

<212> PRT

<213> Homo sapien

<400> 93

Asp Thr Ile Ile Pro Glu Val Pro Gln Leu

1

5

10

<210> 94

<211> 10

<212> PRT

<213> Homo sapien

<400> 94

Glu Val Pro Gln Leu Thr Asp Leu Ser Phe

1

5

10

<210> 95

<211> 8

<212> PRT

<213> Homo sapien

<400> 95

Thr Pro Leu Asn Ser Ser Thr Ile

1

5

<210> 96

<211> 8

<212> PRT

<213> Homo sapien

<400> 96

Ile Gly Leu Arg Trp Thr Pro Leu

1

5

<210> 97
<211> 9
<212> PRT
<213> Homo sapien

<400> 97
Ser Ile Gly Leu Arg Trp Thr Pro Leu
1 5

<210> 98
<211> 9
<212> PRT
<213> Homo sapien

<400> 98
Leu Asn Ser Ser Thr Ile Ile Gly Tyr
1 5

<210> 99
<211> 10
<212> PRT
<213> Homo sapien

<400> 99
Pro Leu Asn Ser Ser Thr Ile Ile Gly Tyr
1 5 10

<210> 100
<211> 9
<212> PRT
<213> Homo sapien

<400> 100
Thr Pro Leu Asn Ser Ser Thr Ile Ile
1 5

<210> 101
<211> 8
<212> PRT
<213> Homo sapien

<400> 101
Ile Gly Tyr Arg Ile Thr Val Val
1 5

<210> 102
<211> 9
<212> PRT

<213> Homo sapien

<400> 102

Ile Ile Gly Tyr Arg Ile Thr Val Val
1 5

<210> 103

<211> 10

<212> PRT

<213> Homo sapien

<400> 103

Thr Ile Ile Gly Tyr Arg Ile Thr Val Val
1 5 10

<210> 104

<211> 9

<212> PRT

<213> Homo sapien

<400> 104

Ile Gly Tyr Arg Ile Thr Val Val Ala
1 5

<210> 105

<211> 10

<212> PRT

<213> Homo sapien

<400> 105

Ile Ile Gly Tyr Arg Ile Thr Val Val Ala
1 5 10

<210> 106

<211> 10

<212> PRT

<213> Homo sapien

<400> 106

Glu Leu Ala Gly Ile Gly Ile Leu Thr Val
1 5 10

<210> 107

<211> 10

<212> PRT

<213> Homo sapien

<400> 107

Glu Ala Ala Gly Ile Gly Ile Leu Thr Val
1 5 10

<210> 108
<211> 10
<212> PRT
<213> Homo sapien

<400> 108
Phe Leu Pro Ser Asp Tyr Phe Pro Ser Val
1 5 10

<210> 109
<211> 9
<212> PRT
<213> Homo sapien

<400> 109
Ala Glu Met Gly Lys Tyr Ser Phe Tyr
1 5

THIS PAGE BLANK (USPTO)